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INTRODUCTION 
Metastasis is the complex process in which tumor cells 
growing at a primary site detach from the primary tumor, migrate 
throughout the body, invade into normal tissue at a distant site, 
and grow into secondary tumors. The process of blood-borne 
metastasis is one of the major obstacles to the treatment of 
cancer, and is illustrated in a general and very simplified 
fashion in Figure 1. The tumor must first invade through normal 
tissue until it reaches a circulatory system, or, as illustrated, 
can induce the formation of its own supply of blood vessels. Tumor 
cells must then migrate through the basement membrane surrounding 
the vessel in order to be released free in the circulation 
(intravasation). The cells must then survive transport in the 
circulation throughout the body, and attach at some distant site. 
Here the tumor cell or cells must again penetrate the endothelium 
and basement membrane (extravasate) and migrate into the normal 
tissue, where the process of growth, invasion, and metastasis 
begins again. It has been estimated that only a very small 
percentage of tumor cells released into the circulation actually 
survive this process and develop into secondary growths. Many 
investigators are studying the mechanisms which allow certain 
r 
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Figure 1. The pathogenesis of metastasis (from Fidler, 1978). 
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tumor cells to successfully complete the difficult metastatic 
pathway in the hope of finding ways to interfere in this process. 
Recently researchers have tried to identify phenotypic 
properties necessary for metastasis by comparing normal cellular 
properties to those of transformed cells from the same tissue or 
by comparing the properties of tumor cells from the same origin 
with different metastatic potential. In this way, it has been 
demonstrated that there is a good correlation between an increase 
in proteolytic activity and an increase of the metastatic 
capability of certain tumor lines. As more information about the 
types of proteolytic enzymes secreted by tumor cells became 
available, roles for their possible involvement in the metastatic 
process were postulated. Due to the complex nature of the 
metastatic process, especially with regards to the number of 
interactions between a metastasizing tumor cell and the host, 
(i.e. immune system, hormones and growth factors, plasma proteases 
and inhibitors, etc.) there have been many suggested points of 
protease action, some of which have been in direct contradiction. 
The process of metastasis can be conveniently divided into several 
distinct steps as illustrated in Figure 1, although it should be 
understood that tumors are heterogeneous and not all tumor cells 
need to complete all of the steps in order for metastasis to 
occur. Proteases have been proposed to be involved in many of 
4 
these steps and there is evidence to support these ideas. Two of 
the major functions which proteases may perform are the 
degradation of normal host tissues which would act as barriers to 
a migrating tumor cell, and the reattachment of the tumor cell 
after it is in circulation. For example, plasminogen activators 
can activate the serum enzyme plasminogen to plasmin, a general 
serine type protease which can degrade many proteins on the 
surface of normal cells and attack many extracellular structures 
such as fibrin and fibronectin. Plasmin has also been shown to 
activate latent collagenase, a metalloproteinase which is 
essential for complete degradation of the basement membrane. It 
has been demonstrated that some tumors secrete a type IV 
collagenase and this proteinase may also be a part of the 
successful metastatic cell's phenotype. Cathepsins, especially B, 
have been shown to correlate in some cases with metastatic 
potential, and they too can degrade a variety of substrates, 
including proteoglycans and type IV collagen by activation of 
latent collagenase. In addition, other proteases, such as 
elastase, cathepsin D, and neutral trypsin-like proteases, have 
been correlated with metastatic potential. These may again be 
involved in degradation of normal host tissue. Thrombin has been 
postulated to play an important role in the reattachment of tumor 
cells by converting fibrinogen to fibrin and thus creating a 
5 
fibrin clot. Many tumors have been shown to secrete factors which 
activate thrombin, and factors which stimulate platelet 
aggregation have also been isolated. This can lead to the 
aggregation of a tumor cell and platelets or other blood 
components. An embolus formed by clumping of tumor cells, 
platelets and fibrin would help to anchor the tumor cell at a 
secondary site where it can invade to form a new tumor. 
Other suggested roles for proteases include, 1) defensive 
mechanisms against the host immune system, 2) facilitating the 
release of tumor cells from the primary tumor by decreasing cell-
cell adhesion, or 3) modification of the cell surface of adjacent 
normal cells. Modification of cell surfaces can stimulate the 
secretion of growth factors or proteinases by the normal cells 
which are necessary for the tumor to metastasize. These factors 
may also be important to the process of angiogenesis, which is 
another important feature of the progression of some tumors. 
Although much evidence has accumulated over the years in 
favor of a crucial role for proteinases in the metastatic process, 
the issue is still not clearly resolved. Many of the results 
consist mainly of correlations with little direct evidence. In 
other cases the literature is contradictory, or at best unclear, 
perhaps because of the many different model systems and types of 
tumors being studied. 
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If proteases are essential to the process of metastasis, it 
may be possible to inhibit the spread of cancer by inhibiting the 
proteases involved. Alternatively, since much of the current 
literature disagrees on the importance of proteases in the process 
of metastasis, it may be possible to determine if specific 
proteases are necessary for metastasis by inhibiting their action. 
However, the inhibition of individual proteases in an .in. .Y1YQ_ 
model for tumor metastasis presents several problems. Some of the 
most potent enzyme inhibitors (i.e., chloromethylketones) are very 
toxic .in. yj.yQ_. Other inhibitors lack the specificity required to 
inhibit a particular enzyme or type of enzyme, thus producing 
results which are not conclusive. In addition, concentrations of 
the inhibitors must be able to be maintained at high enough levels 
to significantly inhibit the protease in order for an effect to be 
observed. Several .in. vitro models have been developed to 
selectively examine steps or stages in the metastatic process, and 
these have yielded valuable information. However, as noted above, 
the overall process of metastasis is very complex, and 
observations made .in. vitro may not be directly relevant to the .in. 
.v.i.vQ situation. 
The goal of this dissertation was to further investigate the 
role of proteolytic enzymes in metastasis utilizing specific 
enzyme inhibitors. Some of these enzyme inhibitors have been newly 
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synthesized in this and other laboratories, and should allow for 
the specific inhibition of implicated proteases. By performing 
these studies in a relevant in .Yi.Y.Q.. model system, it is hoped that 
these results will help to clarify the importance of proteinases 
in metastasis and hopefully lead to a better understanding and 
treatment of neoplastic disease in the future. 
The specific aim of this work therefore, was to examine the 
role of the proteolytic enzymes cathepsin B, plasminogen 
activator, and thrombin in the process of metastasis by inhibiting 
their activity in an in .Y.i.YQ. model system for metastasis. It was 
proposed to accomplish this goal by treating the experimental 
animals with specific proteolytic inhibitors. Because of the 
evidence suggesting that plasminogen activator is important to the 
process of metastasis, and because there exist different types of 
plasminogen activators with different properties, a second aim of 
this project was to identify and characterize the plasminogen 
activator(s) produced by the tumor used in the in .Yi.Y.Q. model. 
LITERATURE REVIEW 
1. GENERAL DISCUSSION OF PROTEASES IN METASTASIS 
Although the role of proteases in metastasis has become a 
very active area of research over the past decade, there are still 
very few clear conclusions to be found in the literature, which is 
now quite extensive in this area ( Strauli ~.al.., 1980; Liotta 
and Hart, 1982; Quigley, 1979a; Nicolson, 1982; Schirrmacher, 
1985). This is due in a large part to the complexity inherent in 
the metastatic process and therefore in any attempts to study it. 
It is also due in part to the large variations between 
investigators in the type of tumors studied and the model systems 
and methods used to investigate them. 
Much of the evidence which supports the theory that increased 
production of proteases is an important component of a tumor 
cell's metastatic potential comes from simple quantitative 
experiments. Many of the earliest experiments compared the amount 
of certain proteases produced by a tumor with the amount produced 
by normal tissue. For example, Recklies ~.al_. (1980) demonstrated 
that explants of malignant human breast tissue maintained in 
tissue culture secreted 10-fold greater amounts of cathepsin B 
8 
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than did similarly maintained explants of normal tissue or 
fibroadenoma. It is interesting to note that in this study, the 
authors detected no difference in the amounts of plasminogen 
activators (PA), collagenase, or cathepsin D. However, Evers ~ 
.ai.. (1982) report a 4-fold increase in PA activity in human breast 
tumors compared to normal tissues. Similarly, Keiditsch and 
Strauch (1970) showed that mammary carcinomas display a higher 
level of collagenase activity in the periphery of the tumor than 
in the central regions, both of which were higher than normal 
surrounding tissue. Among the many explanations for this 
contradiction in the reported levels of proteinases in breast 
tissue, several deserve comment. First, one study (Recklies ~ 
.al.., 1980) maintained the tumor in tissue culture for at least two 
days before assaying for proteinase. The question of whether tumor 
cells .1n yitro are suitable models for .1n.v.iv2. tumors depends on 
the question asked, but is probably most suitably answered in the 
negative. In addition, differences in the preparation of the 
samples, the assays used for plasminogen activator, the size and 
stage of the tumor growth and the presence of normal host cells 
and/or proteinase inhibitors make interpretation of any study 
using tumor tissue difficult. Two of these authors also compared 
the amounts of protease secreted by primary tumors and metastases; 
Recklies ~~. (1980) finding one third the amount of cathepsin B 
10 
in metastasis and Evers~ .al_. (1982) finding no significant 
difference in PA levels. These early observations are significant 
in light of experiments performed by Colombi ~.al. (1984) which 
demonstrate a very high level of PA activity in adenocarcinoma 
tissue, but very low levels of plasma PA activity in patients 
bearing metastasis. The authors suggest that the tumor secretes 
high levels of PA in the peritumor space to degrade normal tissue, 
but once in the circulation, decreased levels of PA increase the 
chances of the tumor attaching by means of a fibrin clot, and 
hence increases the chance of metastasis. This illustrates that 
certain tumor cells may vary the secretion of proteases depending 
on their environment, or that more than one of the heterogeneous 
cell populations found in a tumor may act in a concerted manner 
to produce metastasis. There are many other reports in the 
literature which quantitate the amount and type of protease in 
tumor samples and compare it to that found in normal tissue, or 
compare the proteases secreted by malignant tumors with the 
proteases secreted by nonmalignant tumors of the same type (i.e., 
Wilson and Dowdle, 1978; Wilson ~.al.., 1980; Kirchheimer ~ .aJ...., 
1985; Sloane and Honn, 1984). In the majority of these, a positive 
correlation between the invasive state and protease production is 
observed. In some cases this correlation is not observed, but 
because of the problems with obtaining homogeneous samples of 
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tumor tissue, free from contaminating normal cells, proteases, or 
inhibitors, these results can all be questioned. 
An interesting method to overcome some of these problems is 
to use labeled probes (radioactive or fluorescent antibodies or 
inhibitors) directed against the protease under study, and examine 
fixed sections of tumors, where the normal cells can be clearly 
identified. Recently, urokinase (UK) has been localized in Lewis 
Lung tumors to areas of invasive growth and degradation of normal 
tissue using antibodies directed against the enzyme (Skriver ~ 
.a.J...., 1984). This method has also been used to look at the amounts 
and location of proteases on tumor cells in culture (Kozlowski ~ 
.a.J...., 1984). Results from these types of studies clearly show in 
some instances large increases in the amount of proteases on the 
surface of tumor cells, a result which will be discussed further. 
Because of the difficulties involved in studying samples of 
ill .Y1YQ. tumors, many researchers have studied the production, 
secretion, and properties of tumor produced proteases utilizing 
tumor lines maintained in culture. Again, most researchers find an 
increased amount of proteolytic activity associated with the tumor 
cells compared to their normal controls (Sloane and Honn, 1984; 
Dano~ .aJ..., 1985). And again there are studies which fail to find 
a correlation, and reasons why this correlation might not be seen. 
Some enzymes are secreted as zymogens and if not activated before 
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the assay, their activity would not be correctly measured. Also, 
some cells produce both a certain protease and an inhibitor for 
that enzyme (Roblin tl.sl.., 1978), and again, the question of the 
amount of protease produced under ill yitro conditions as opposed 
to the amount produced ill.v.1Y2. when the cell is actually in the 
process of invasion may make measurements of this type less than 
conclusive. This is especially important when it is realized that 
tumor cells change their phenotype rapidly and adapt to culture 
conditions, which can result in a change in metastatic ability 
(Honn tl .sl_,, 1986; Miner tl .aJ..., 1982). 
Using the same primary tumor, it has been possible to select 
for sublines which vary in their metastatic ability and /or target 
organ of metastasis. This has provided another model for studying 
properties associated with the metastatic phenotype. The best 
known group of these sublines are those developed from the B16 
melanoma originally isolated by Fidler (Fidler, 1973). By various 
selection procedures, which usually include injection into 
animals, collection of metastases, growth in culture, and 
reinjection into animals, lines selected for high lung 
colonization, increased invasion, brain metastasis, ovary 
metastasis, and others have all been developed (Fidler, 1973; 
Hart, 1979; Nicolson, 1982). Using these lines, different authors 
have demonstrated a correlation between metastatic potential or 
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invasion and many different properties, including increased PA, 
cathepsin B, type IV collagenase, Factor X activating enzymes and 
beparanase activity (Wang .e.t_ .al., 1980; Sloane .e.t_ .sJ..,, 1981; 
Liotta et .al_,, 1980a; Gilbert and Gordon, 1983; Nakijima ~ .aJ...,, 
1983). In addition, at least one study (Nicolson~ .a.l_,, 1976) 
showed no correlation between plasminogen activator and 
metastasis, although all lines produced higher levels than normal 
cells. Since PA's activate a cascade type mechanism, it may be 
that only small amounts of PA are needed in order to enable a cell 
to metastasize, and other factors may determine the efficiency of 
the process. 
2. PLASMINOGEN ACTIVATORS AND METASTASIS 
In addition to the general experiments discussed above, there 
exists a large body of literature dealing with the roles of 
specific proteinases in metastasis. PAs are one of the most 
studied of these enzymes, and several recent reviews discuss these 
results in detail (Dano ~ .iill_., 1985). There exist two distinct 
types of PAs in mammalian systems, the urokinase type and the 
tissue type (tPA). tPA is normally produced by endothelial cells 
lining the blood vessels and is believed to be involved in 
maintaining hemostasis. Urokinase type PA was originally purified 
from urine, but seems to have a more general role in tissue 
degradation and is produced by a number of normal cells during 
tissue remodeling processes. Both enzymes are serine proteases 
which act by cleaving the proenzyme plasminogen at a specific Arg-
Val bond to generate the serine protease plasmin, which has a 
broad trypsin-like specificity. Plasminogen, which is produced by 
the liver, is known to occur throughout the body in significant 
quantities and can thus act as a large reserve of proteolytic 
activity. Plasminogen is the only known protein substrate of PAs. 
Both UK and tPA have been purified from a number of sources. 
Antibodies do not cross react between the two types of enzyme, but 
14 
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antibodies against one type will cross react with the same type 
enzyme from another species. The human enzymes have been cloned 
and sequenced and their position on the chromosome is known 
(Rajput ~.al_., 1985). The gene for murine UK has also been cloned 
(Belin ~.sJ..., 1985). Both types of enzymes have also been shown 
to exist in various forms. Human UK is secreted as a one chain 
protein of Mr 55,000, which although analogous to the proenzyme 
form of most serine zymogens, has recently been shown to be active 
against its native substrate, plasminogen (PLG) (Lijnen ~ .al_., 
1986). The one chain form is not active against small substrates, 
and shows low reactivity with inhibitors. In plasma, the 
activation of plasminogen by one chain UK is inhibited, and this 
inhibition can be neutralized by the formation of a fibrin clot. 
When cleaved by plasmin, the UK exists as a fully active 2 chain 
molecule of the same Mr and also as an active, partially degraded 
form of Mr 30,000. The tPA, (which has been shown by DNA 
sequencing to be very different from UK), is likewise produced in 
a one chain form which is reported to be partially active, 
although some experiments indicate it may not be (Andreasen~ 
.al_., 1984). This enzyme has a Mr of approximately 70,000 and can 
be cleaved to a more active 2 chain form by the action of plasmin. 
Again, the activity of tPA towards plasminogen is increased in the 
presence of fibrin, and this has important implications to the 
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natural regulation of PA activity. A partially degraded form of 
tPA which retains activity has also been reported (Dano ~.al.., 
1985). In the human, both enzymes are glycoproteins. In the mouse, 
the UK type is not glycosylated, which results in a slightly lower 
Mr of approximately 48,000 (Belin~ .al.., 1985). The larger tPA 
molecule contains additional peptide sequences, recently located 
on the heavy chain (Rijken and Groeneveld, 1986), which are 
responsible for this enzyme's high affinity for fibrin clots. 
Although some tumor cells secrete increased amounts of tPA, 
urokinase is the type of enzyme most usually found associated with 
tumors, although in earlier studies antibodies were not always 
available to distinguish between the two types. One of the 
arguments that support the role of UK in the invasion and spread 
of cancer is the fact that UK is often produced by cells 
undergoing normal processes of invasion and tissue destruction. 
Thus in the involution of mammary glands after the cessation of 
lactation, Ossowski ~.al.. (1979) showed a good correlation 
between an increase in UK PA in the mammary gland tissue and the 
process of involution. This was demonstrated temporally by varying 
the time at which the litters were removed and also by using 
hormone combinations which affected the beginning of involution 
and UK PA production in the same manner. It has been suggested 
that the process of involution is very similar to the invasion of 
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neoplastic cells, as in both processes a substantial amount of 
tissue destruction takes place, including the degradation of 
basement membrane structures. Evidence of the same nature also 
shows that PAs are probably involved in several stages of the 
reproductive cycle, including the production of PAs by granulosa 
cells and the oocytes in the process of follicle disruption, the 
implantation of fertilized eggs into the uterus (trophoblast 
invasion), and possibly the penetration of sperm into the egg 
(Huarte .e.t_ .al., 1985). Another example of normal cells utilizing 
UK to invade comes from studies which show that stimulated 
macrophages and polymorphonuclear leukocytes produce UK, whereas 
the unstimulated cells do not (Werb .e,t..s.l..., 1980). Thus there 
exist normal situations analogous to the invasion of a tumor cell 
into normal tissue in which it appears that PAs, particularly UK, 
are intimately involved. This is an important consideration in 
view of the fact that this situation has not yet been shown to 
exist for some of the other proteinases implicated in the process 
of metastasis, with the possible exception of collagenase. 
It is also significant to note that by activating 
plasminogen, UK may be triggering a cascade of proteolysis, since 
plasmin has been shown to activate latent collagenase (Paranjpe ~ 
.s.l_., 1980) and possibly other proenzymes as well. Thus PAs are 
well suited to their proposed role of destroying normal tissues, 
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including basement membrane type IV collagen. In addition, plasmin 
has been shown to be capable of modifying a number of normal 
cellular properties by altering cell surface components. For 
example, plasmin treatment can stimulate cells to divide, to 
secrete various factors, or even to secrete additional proteases 
(Werb and Aggeler, 1978). Plasmin has also received some interest 
as an enzyme which may cleave host produced antibodies against the 
tumor cell (Latner tl .aJ..., 1974). 
The study which perhaps most strongly indicates that PAs are 
necessary for the process of metastasis was performed by Ossowski 
and Reich (1983). These experiments studied the invasion and 
metastasis of human carcinoma cells grown on the chorioallantoic 
membrane (CAM) of chicken embryos. In this model system, the tumor 
cells invade through the CAM, penetrate into the circulation, 
lodge in the lungs and develop into metastasis. The authors showed 
that the carcinoma produced significant amounts of UK type PA. 
Injecting the embryo with a specific inhibitory antibody against 
the carcinoma UK reduced the number of metastasis drastically (in 
some experiments, by 95%). Although this experiment seems to 
conclusively indicate an important role for UK, it must be taken 
into consideration the non-homology of the system used. A human 
carcinoma growing on a chicken egg is in a significantly different 
environment than a human carcinoma growing in a human. In a recent 
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abstract (Ossowski and Wilson, 1986), the authors have reported 
similar results with the same carcinoma line in nude mice, but 
again, the immune system plays an important role in metastasis and 
can not be ignored. However, the use of a specific inhibitory 
antibody is a promising approach which has produced strong 
evidence for the importance of UK to the process of metastasis. 
In another system, these authors have shown that 
hydrocortisone, which suppresses the synthesis of PA by mouse 
mammary tumors in yitro, also inhibits the growth and incidence· of 
these tumors ..i...n .v.iY.Q. (Mira-y-Lopez tl ~., 1985). One common 
criticism that this study shares with others of this nature is 
that the question of whether hydrocortisone is inhibiting the 
synthesis of UK and consequently inhibiting tumor growth, or if 
hydrocortisone is somehow affecting the growth of the tumor and 
consequently inhibiting the release of PA, is not clear. It was 
mentioned above that the production of UK by normal mammary gland 
tissues is also regulated by hormones, which further complicates 
this issue. In either case, it is apparent that an increase in the 
production of plasminogen activator is closely correlated to the 
growth of this particular tumor. 
Further studies on the importance of PA to metastasis attempt 
to show a coordinate modification of PA production and 
tumorigenicity. In one of these, a clone of the B16 melanoma was 
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shown to have a decreased ability to form tumors when grown in 
culture medium containing 5-bromodeoxyuridine {Christman ~ .a.J...., 
1975). It was subsequently shown that these cells also showed a 
coordinate decrease in PA expression when grown in 5-
bromodeoxyuridine. These changes were both reversible. In 
addition, a clone maintained in 5-bromodeoxyuridine which 
permanently lost its tumorigenecity also produced no detectable 
PA. It should be noted here that as in most studies or this type 
another group reported the opposing view. Using a Syrian hamster 
melanoma which only displayed transformed characteristics in the 
PRESENCE of 5-bromodeoxyuridine, Rosenthal ~ ~. (1975) report 
that PA was again suppressed by 5-bromodeoxyuridine, and therefore 
not associated with transformation. However, this paper did not 
give any details about whether this mutant line was actually 
tumorigenic. This study also illustrated that at different stages 
or growth in culture, different levels of PA were produced. This 
phenomena has been observed by other authors as well and may again 
be a reason for discrepancies between research groups. Further 
studies with the mouse melanoma line suggests that cocultivation 
of nontumorigenic and tumorigenic lines results in a suppression 
of PA production by the tumorigenic line {Newcomb~ .al_.,1978). 
Furthermore when this mixture of cells was innoculated into 
immunocompetent mice, tumor production was suppressed; however the 
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same mixture produced tumors in immunodeficient mice. This may 
indicate a role of plasminogen activator-plasminogen (PA-PLG) 
proteolysis in the protection of tumor cells from the immune 
system • In another model system, using clones of a rat mammary 
carcinoma, a strong correlation between PA activity and metastatic 
potential was also observed (Carlsen~ .sY..., 1984). In this study 
there seemed to be a threshold level of PA activity, and clones 
with PA levels higher than this threshold produced high numbers of 
metastases. 
Stronger evidence for the involvement of PAs in metastasis, 
which may or may not hold up to further scrutiny by the scientific 
community, comes from viral transformation studies. Some of the 
earliest evidence for a role of PAs in metastasis came from work 
done on viral transformation by Rifkin and Reich. They showed that 
transformation of chick embryo fibroblasts by Rous sarcoma virus 
(RSV) results in the production of UK (Unkeless ~ .sY,.., 1973), 
which is not produced by the normal fibroblasts. This production 
of UK is dependant on the development of transformation since in 
cells infected with non-transforming RNA or DNA viruses, no 
increase in UK is seen. Likewise when cells were infected with a 
temperature sensitive mutant strain of RSV which only produced 
transformation at the permissive temperature, PA production was 
also increased only at the permissive temperature. PA production 
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and transformation were both reversible with changes in 
temperature, and the increase in PA was the earliest biochemical 
event detected after transformation. Ossowski~ .al,. (1974) showed 
that the morphological changes observed upon transformation 
depended on PA-PLG activity. In addition, the tumorigenecity of 
virally transformed cells in nude mice has been shown to correlate 
with PA activity. Again, some authors have claimed to the contrary 
that temperature sensitive variants produce tumors even at the 
non-permissive temperature (Poste and Flood, 1979), and that the 
production of plasminogen activator is not related to 
tumorigenicity using these same strains (Wolf and Goldberg, 1978). 
However closer examination shows in the case of the temperature 
sensitive mutants (Poste and Flood, 1979) the production of PA was 
not actually measured under the conditions of the tumor formation, 
and in the second case (Wolf and Goldberg, 1978) all of the lines 
which produced tumors in the absence of high PA production grew as 
noninvasive tumors encapsulated in a tough fibrous coat. Thus, 
although the literature shows a close correlation with PA 
production and transformation, PA production may not be necessary 
for tumorigenicity, depending on the system used. However, even in 
cases of low PA production there seems to be a strong indication 
that its action may be necessary for invasive growth of the tumor. 
Similar results have been reported using other viruses and cell 
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lines, and increased PA activity has also been observed in cells 
transformed by chemical carcinogenesis (Dano tl .al_., 1985). 
In other studies, the expression of PAs has been shown to be 
modulated by hormones in hormone sensitive tumors (Ossowski tl 
.aJ..., 1979), to be induced by damage to cellular DNA (Miskin and 
Reich, 1980), and also to be stimulated by tumor promoters such as 
phorbol myristate acetate. Goldfarb and Quigley (1978) have shown 
that phorbol myristate acetate treatment increases the synthesis 
of PA in normal cells, resulting in morphological changes, and 
also increases the already high production of PA by transformed 
cells. Again, this evidence only supports a correlation between PA 
production and transformation or tumor growth. Likewise it has 
often been demonstrated that there is usually a good correlation 
between production of plasminogen activators and other of the 
transformation phenotypes studied in culture, such as anchorage 
independent growth, reduced cellular adhesiveness, and increased 
cell migration (Quigley, 1979b). 
Another model system which has been used to study the role of 
proteinases in invasion and metastasis developed by Liotta uses a 
human amnion membrane to quantitate tumor cell invasion through a 
basement membrane (Liotta tl.sl..., 1980b). Although in most studies 
using this system, collagenase is the only proteinase shown to 
correlate with invasion, recent evidence indicates UK may also be 
24 
important. Rifkin (1986) reports that anti-UK (but not anti-tPA) 
antibodies prevented invasion of the amnion by B16 cells. An 
important consideration in interpreting these results is of course 
the lack of many i..n.YiY.2. factors, and the fact that most 
investigators perform these studies under slightly different 
conditions. 
3. CATHEPSIN B AND METASTASIS 
Although the evidence for an important role of cathepsin B in 
metastasis is not as extensive as that for PAs, research in this 
area indicates that cathepsin B is important in at least some of 
the tumor systems studied (Sloane ~.ill.., 1986). Cathepsin B is a 
cysteine protease with a Mr of approximately 25,000 and a broad 
endopeptidase activity. Normally found in the lysosomes, cathepsin 
B has a major function in the degradation of proteins. Cathepsin 
B has an acidic pH optimum of around 6, and is subject to rapid, 
irreversible denaturation above pH 7. Lysosomal proteinases in 
general may be increased in metastasis, and the possible existence 
of "extracellular lysosomes" may be significant in this respect. 
However, very little evidence exists on this subject. Original 
work in this field was dedicated to confirming that the existence 
of cathepsin B activity within tumors was a property of viable 
tumor cells, and not just an artifact from tumor cell necrosis or 
invasion of normal phagocytotic cells. Also, there were 
difficulties with explaining how a protease, usually intracellular 
and inactive at neutral pH could be involved in extracellular 
destruction. Thus it is significant that a cathepsin B-like 
protease with slightly different properties than the normal 
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protease has been described (Sloane iU_ .aJ..., 1984, Mort iU_ Al_., 
1980). This enzyme has increased stability at higher (above 
neutral) pH and appears to be localized in the plasma membranes, 
as well as the lysosomes, and perhaps exists in a shed or secreted 
form. The enzyme is often found in a latent form which can be 
activated by pepsin treatment and/or a higher Mr form 
(approximately 40,000). The enzyme is immunologically cross 
reactive with cathepsin B under appropriate conditions, and so is 
described as a pro-cathepsin B or cathepsin B-like enzyme. 
Cathepsin B is capable of degrading the non-helical portions of 
collagen, fibronectin, proteoglycans and can also activate latent 
collagenases and therefore, like PA, is capable of initiating a 
proteolytic cascade. Increased secretion of a cathepsin B-like 
protease would therefore enable a tumor cell to degrade most 
extracellular structures that a migrating tumor cell may 
encounter. There is also evidence that cathepsin B localized in 
membranes may be resistant to plasma protease inhibitors (Sloane 
and Honn, 1984). Because of these properties, it is reasonable to 
propose that extracellular cathepsin B may play a role in the 
invasion of tumors, even in an environment (high pH, proteinase 
inhibitors) where lysosomal cathepsin B would not be active. 
Similarly to PA, there is accumulating evidence that 
cathepsin B may be involved in non-neoplastic tissue destruction. 
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Early evidence correlated higher levels of cathepsin B activity in 
tissue remodeling and inflammation (Nakagawa ~.ill_., 1977; Bayliss 
and Ali, 1978; Davies ~.al,.., 1978). However, these studies did 
not distinguish between intra- or extra- cellularly located 
cathepsin B and therefore may simply represent an increase in 
lysosomal activity in these conditions. Recently, Recklies and 
Mort (1985) have demonstrated in culture medium from lactating 
mammary gland explants the existence of stable, active, high 
molecular weight forms of both cathepsin B and L. These authors 
propose that the secreted immunologically related precursor forms 
may represent an abnormal form which is incompletely processed. It 
is interesting to note that these authors found hydrocortisone 
inhibited the release of the cathepsin B-like enzyme from normal 
mammary gland explants in culture (Recklies ~.sJ..., 1985) in much 
the same way that Ossowski ~.al. (1979) showed for PA. This 
illustrates that the practice of studying only one of the various 
proteases involved in the complicated process of metastasis may 
lead to incorrect conclusions. Further support for a normal 
physiological extracellular role of cathepsin B or a cathepsin B-
like protease comes from a paper by Gordon ~.sJ... (1985) which 
demonstrates, in cultures of a human hepatoma line, that a Mr 
54,000 protease immunologically and enzymatically related to 
cathepsin B may be responsible for the the removal of a prosegment 
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from proapo-lipoprotein-A-II. This indicates that a "procathepsin 
B-like" proteinase can accurately process natural protein 
substrates, and may function extracellularly in normal cells. 
As mentioned above, several studies have correlated an 
increase in the amount of cathepsin B with tumor homogenates as 
compared to homogenates of normal tissues. Histochemical studies 
by Sylven ~.al.. (1974) have shown the presence of cathepsin B-
like material on the surface of a variety of tumor cells using an 
immunological technique. Poole~ .al_. (1978) have demonstrated 
that the invading edges of breast tumors have a higher cathepsin B 
activity than the center of the malignancy. This localization 
would be expected if cathepsin B were playing an essential role in 
tumor invasion, but it does not provide causal evidence. 
Increased cathepsin B has also been correlated with increased 
spontaneous metastasis and lung colonization in selected sublines 
of the B16 melanoma and murine Lewis Lung carcinoma (Sloane and 
Honn, 1984). There also exist reports in which this correlation 
failed to be demonstrated (Sloane and Honn, 1984), possibly 
because of similar problems in measuring the amount of cathepsin B 
in ~ ~ homogenates, or in variations induced by growing the 
cells in culture in order to assay cathepsin B levels. 
It has also been reported that agents which modify the 
metastatic potential of cell lines concomitantly affect cathepsin 
29 
B activity. Takenaga (1984) demonstrated that dimethyl sulfoxide 
(DMSO) increases the ability of Lewis Lung carcinoma to form 
experimental metastasis and also increases the amount of cathepsin 
B activity. However, treatment of this clone with DMSO also 
resulted in increased activities of other proteases, including 
plasminogen activator. Likewise a group of murine 
methylcholanthrene-induced fibrosarcomas had elevated cathepsin B 
activity compared to normal muscle (McLaughlin ~.aJ..., 1983). The 
levels of cathepsin B activity did not correlate with metastatic 
potential. However, the authors point out that increased 
proteolytic activity may be important to some aspect(s) of 
metastasis, and still not correlate with the overall process. 
In experiments using the amnion membrane model in 
collaboration with Dr. Persky (Persky ~.al.., 1986), it was shown 
that a strong inhibitor of cathepsin B had no effect on invasion 
and migration through the basement membrane. This result is in 
agreement with that of other researchers using this model (Rifkin, 
1986). This lack of an inhibition of invasion suggests that 
cathepsin B may not be involved. Alternatively, an effect may not 
be detected because of other reasons. For example, the location of 
cathepsin B in this system may be unavailable to small inhibitors 
of the type used (leupeptin), the cathepsin B activity may only be 
required for tumor invasion .i.n.~, or the "pro" form of the 
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enzyme secreted may be resistant to the inhibitor used. 
In summary, although the number of experiments which support 
an important extracellular role of cathepsin B in tissue 
destruction by tumor cells is not as large as that for PA, the 
experiments follow the same type of methodology and generally 
support the involvement of cathepsin B in metastasis. Further 
research to clarify the role of this enzyme is therefore of 
significant interest. 
4.THROMBIN AND METASTASIS 
Thrombin is another protease which is believed to be involved 
in the process of metastasis and host responses to tumors. The 
role of thrombin in hemostasis is becoming increasingly more 
complex, and the role which this enzyme may play in metastasis is 
at present unclear. Thrombin is a 34,000 dalton serine protease 
responsible for cleaving fibrinogen to fibrin at a single arg-gly 
bond, which results in the initiation of clot formation (Stryer, 
1981). Thrombin is produced from inactive 66,000 dalton 
prothrombin by the action of another serine protease of the 
coagulation cascade, Factor Xa. Factor X can be activated by 
either the intrinsic or extrinsic pathway and so this is the first 
common step of the two pathways leading to coagulation. Unlike PA 
and cathepsin B, thrombin is not a tumor produced protease, but 
many cancer patients have coagulation disorders and many tumors 
have been shown to directly cause the activation of the 
coagulation cascade (Rickles and Edwards, 1983). Other properties 
of thrombin which may or may not be important to the metastatic 
process include evidence that (1) thrombin can stimulate the 
synthesis and secretion of a collagenase inhibitor from platelets 
and a PA inhibitor from platelets and endothelial cells (Cooper ~ 
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~' 1985; Gelehrter and Sznycer-Laszuk, 1986), (2) thrombin 
initiates cell proliferation (Carney ~.al., 1985), (3) thrombin 
bound to thrombomodulin can activate protein C, which will result 
in increased fibrinolytic activity by degrading an inhibitor of 
PAs (Maruyama and Majerus, 1985), (4), thrombin can release 
proteoglycans from endothelial cells, and (5), thrombin can 
stimulate endothelial cells to secrete prostacyclins and tPA to 
again stimulate fibrinolysis (Shimada and Ozawa, 1985). 
In metastasis, thrombin is proposed to increase the 
percentage of tumor cells released which survive transport in the 
circulation and attach to grow into secondary tumors (Markus, 
1984). By forming a fibrin clot around the tumor cells, thrombin 
can lead to the aggregation of platelets and other blood 
components. This fibrin/platelet covering can protect the 
circulating tumor cell from the host immune system by masking the 
cell surface antigens. The larger embolus is also believed to be 
more easily anchored and the tumor cell can than extravasate from 
this stationary phase and continue to grow into a secondary tumor. 
It should be noted that the postulated role for thrombin and 
fibrin formation is in direct opposition to the postulated role of 
PAs. However, the possibility that tumor cells may display 
different phenotypes at different stages in the metastatic process 
must again be considered. Thus in the primary tumor, which is 
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being surrounded by a fibrin clot and in general is under 
increasing pressure to invade and expand, a high 
fibrinolytic/degradative activity may be favored. Once released 
into the circulation, where tumor cells do not survive very long, 
the formation of a protective fibrin clot/platelet embolus may be 
favored. After attachment, the degradative processes may again be 
the pathway leading to successful metastasis. The action of 
thrombin can, by this hypothesis, promote or retard the formation 
of metastasis, depending on the local stage of the process. These 
opposing pathways may also be responsible for some of the 
contradictory experimental results. 
Evidence for the role of fibrin function in the primary tumor 
is limited at this time. Histological studies however have 
generally revealed a fibrin structure surrounding primary tumors, 
and when looking at a malignant tumor, places of local dissolution 
or absence of this structure, as well as the basement membrane, 
are apparent. In addition, studies such as the one by Colucci ~ 
.Ql.. (1981) give support to the theory that under these conditions, 
the fibrin observed is an impediment to tumor migration and 
metastasis. In their studies, different sublines of a murine 
sarcoma of varying spontaneous metastatic potential were shown to 
display an inverse correlation between ability to metastasize and 
ability to activate coagulation of plasma. This activation was 
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proposed to be due to a tissue factor, and the authors concluded 
that the fibrin acts as a barrier to the primary tumor. Other 
tumors have been shown to produce a tissue factor; however several 
of these studies used tumor extracts which may have contained host 
derived tissue factor. For example, macrophages have been shown to 
express increased tissue factor activity when stimulated by the 
presence of cancer, and the fibrin formed may affect macrophage 
migration. Studies which attempt to correlate the amount of tissue 
factor with metastatic potential may therefore not actually be 
measuring tumor tissue factor. 
In an interesting series of experiments, Tanaka~~. (1982) 
tested the effects of tranexamic acid and UK injections on the 
spontaneous and experimental metastasis of several tumor lines. 
When rabbits received i.v. injections of V2 carcinoma cells, 
treatment with UK reduced the number of pulmonary metastases. When 
rabbits with primary V2 footpad tumors received i.v. UK, the 
number of lymph node metastases was increased. In further studies 
using the Lewis Lung carcinoma, these authors again reported an 
increase in lung metastases from a primary footpad tumor when the 
animal was treated with UK, but also reported a decrease in lung 
metastases when the animals received tranexamic acid, an inhibitor 
of the plasminogen to plasmin conversion. Thus there is strong 
evidence for the proposal of conflicting roles for fibrin, and 
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therefore thrombin, in metastasis; a suggested inhibitory role of 
fibrin in the early stages and an enhancing role of fibrin in the 
later stages. It is interesting that in experiments using a 
spontaneous model, injection of UK did not prevent tumor cells 
from lodging in the lungs in larger numbers, but inhibition of 
fibrinolysis did prevent them from escaping the primary tumor. 
This would suggest that the local degradation of surrounding 
fibrin may be more important to the process of metastasis then 
that of fibrin formation and attachment. It may be that 
attachment is controlled by other factors, such as damage to the 
endothelium and exposure of laminin (Terranova~ .sJ..., 1982). 
However, other studies (see below}, have not always supported this 
hypothesis. 
There are also a number of studies which utilized inhibitors 
of coagulation such as heparin or warfarin, or perhaps more 
drastic measures such as infusion of plasmin or defibrinogenation 
of the animal, to attempt to determine the role of thrombin and 
fibrin formation in metastasis. Because of the many possible side 
effects of these treatments, results from these experiments will 
only be summarized here. In general, treatment with an inhibitor 
of thrombin (or in some cases, inhibitors of platelet aggregation 
(Honn~ .sJ..., 1986) reduce the number of metastasis. These studies 
are usually most convincing when performed on i.v. injected cells. 
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In spontaneous models, the results are less clear, and often 
questionable because the drug used has other effects on the 
primary tumor besides the inhibition of thrombin (Markus, 1984). 
For example, heparin has been shown to be antimitotic, to 
facilitate immune responses (Gorelik~~' 1984), and to have 
profound influences on angiogenesis (Folkman, 1985; Folkman~ 
~' 1983). Warfarin inhibits the synthesis of many proteins and 
by decreasing the formation of -carboxyglutamate may have 
pleotropic effects (Hilgard, 1977). 
Recently a number of tumors and tumor lines have been shown 
to produce a cysteine protease which is capable of directly 
activating Factor Xa (Gordon and Cross, 1981; Falanga and Gordon, 
1985). This activity has been purified from extracts of the V2 
carcinoma, and similar factors have been reported to occur in 
tissue extracts of human breast, colon, kidney, vagina and lung 
cancer, transformed hamster fibroblasts, Lewis Lung carcinoma, B16 
murine melanoma, and Ehrlich ascites JW sarcoma cells. This cancer 
"procoagulant" has not been found in extracts of normal tissue. 
Using murine B16 melanoma and Lewis Lung tumor cells, Tohgo ~~ 
(1985) have shown the importance of this procoagulant in the 
probable mechanism for platelet aggregation. And in several 
examples, including selected sublines of the B16 melanoma (Gilbert 
and Gordon, 1983), platelet aggregation has been shown to 
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correlate with metastasis. Further research into the occurrence 
and possible function of this interesting proteinase will 
certainly be forthcoming. 
Evidence such as that briefly presented here demonstrates the 
profound influence of the hemostatic state of the host on cancer 
invasion and metastasis. It is clear that tumors or transformed 
cells are capable of causing the activation of both the 
coagulation and fibrinolytic pathways, perhaps at different 
stages. In a study by Kohga (1978) of ten rat ascites lines, the 
highest incidence of metastases after i.v. injection was obtained 
from the cells with both the highest fibrinolytic and 
thromboplastic activities. Before it is possible to clinically 
interfere in these processes, it is also clear that much more 
research on the actual mechanism of cancer metastasis needs to be 
done in order to identify the crucial steps or times for 
intervention. 
5. PREVIOUS INHIBITOR STUDIES 
One of the most exciting prospects of research on the 
mechanism of tumor cell metastasis is the hope that an increased 
understanding will lead to treatment modalities which may prevent 
this process. Based on the evidence currently available, 
researchers have attempted to reduce metastasis through the use of 
protease inhibitors. Demonstration of a clear reduction of 
metastasis by inhibition of a particular protease would also 
provide conclusive proof that the enzyme was participating and 
further our understanding of the metastatic process. 
Alternatively, lack of an effect would indicate that the protease 
was not essential to the overall process. Experiments performed to 
determine if protease inhibitors do have antimetastatic effects 
have yielded mixed results. Because of the complex nature of 
metastasis and the possible interplay of various host systems and 
the many proteolytic cascades, many of these studies cannot be 
clearly interpreted. Some of these have been mentioned already, 
additional examples are discussed below. 
Although .1.n. yitro experiments may have limited relevance to 
an .1.n. Yi.v.Q. process, they do provide valuable preliminary evidence. 
Various inhibitors of proteases have been tried in all of the .in 
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yitro model systems discussed, again with various degrees of 
effectiveness. In collaboration with Dr. Persky (Persky ~ .s.J..., 
1976), it was shown that high concentrations of urokinase and 
cathepsin B inhibitors had no significant effect on the invasion 
of B16 melanoma cells through an amnion basement membrane. It was, 
however, possible to completely inhibit invasion by the use of 
ethylenediamine tetraacetic acid (EDTA), an inhibitor of 
metalloenzymes such as collagenase. Rifkin (1986) has also 
reported no effect of leupeptin on the invasion of B16 cells in 
this system, and a complete inhibition by EDTA. However, he was 
also able to inhibit invasion using an anti-UK antibody, but not 
with an anti-tPA antibody. Since leupeptin at high concentrations 
inhibits UK, the use of an antibody to inhibit UK must differ in 
some way. Perhaps UK is not completely inhibited by the reversible 
inhibitor leupeptin, especially when the cells are bound tightly 
to the amnion, or the antibody may have other effects which result 
in the differences observed between the two studies. Collagenase 
has also been shown to be important by the work of Thorgeirsson §!. 
.al.. (1982). Quigley has also studied the effects of proteinase 
inhibitors on the degradation of extracellular matrix by tumor 
cells utilizing metabolically labeled subendothelial matrix 
synthesized by normal chicken embryo fibroblasts (Quigley ~.s.J..., 
1986). In this system, aprotinin has no effect unless plasminogen 
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is present, in which case aprotinin normalizes the rate to that 
observed without added plasminogen. Diisopropylfluorophosphate 
(DFP), L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-
64), and 1,10-phananthrolone, all show some inhibition of the 
degradation, however, even with all three inhibitors present, some 
degradation still occurs. This indicates that either the cells are 
producing protease in a localized way in an area where they are 
inaccessible to the inhibitors, or the cells are producing a 
protease which is not sensitive to the inhibitors used. Pearlstein 
~,al.. (1981) showed that a specific thrombin inhibitor 
(dansylarginine N-(3-ethyl-1,5-pentanediyl)amide could inhibit the 
action of thrombin activated by tumor cells and thereby prevent 
their aggregation with platelets. DiStefano ~,al.. (1982) 
demonstrated leupeptin inhibition of a membrane protease involved 
in lysing of normal red blood cells by tumor cells, as did Zucker 
~ .aJ... (1985) using EDTA and minocycline (inhibitors of 
metalloproteinases). These experiments, as well as many others not 
mentioned here, show that specific steps in metastatic processes 
can be blocked by protease inhibitors, and it is reasonable to 
assume that a similar situation exists in~. 
Several important factors must be taken into account when 
attempting to inhibit proteases .in~. First, unlike in a test 
tube, the inhibitors must be free of toxic effects, both to the 
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host and to the tumor cells. Secondly, the inhibitors must show 
specificity towards the protease of interest. This is a major 
drawback of most of the studies reported so far. Many of the 
components of the complement, coagulation and fibrinolysis 
pathways have identical or similar primary specificity, 
principally for the basic amino acids arginine and lysine. Thus an 
inhibitor like leupeptin is effective against more than one of the 
enzymes postulated to be involved in metastasis. Leupeptin is a 
potent inhibitor of cathepsin, but at higher concentrations it can 
also inhibit many other enzymes (for further discussion see 
results). 
An interesting report by Gasic ~.al.. (1983) used an extract 
of leech salivary gland to inhibit lung colonization by Sarcoma 
T241 cells. The extract was shown to contain anticoagulation and 
antiproteinase activities, however other anticoagulants (heparin 
or atroxin) did not result in a significant inhibition of 
colonization. Thus these authors conclude the antiproteinase 
activity of the extract is responsible for the inhibition of 
experimental metastasis, however, the proteases involved cannot be 
identified. 
Leukocyte neutral protease inhibitor (LNPI), shown to inhibit 
collagenase, elastase and chymotrypsin-like neutral protease, was 
reported to significantly inhibit the spontaneous metastasis of 
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Lewis lung carcinoma (Giraldi ~.al., 1977a). Further studies are 
needed to identify the enzyme(s) inhibited in this system. Giraldi 
~.al.. (1977b) also reported an inhibition of metastases formation 
from Lewis lung carcinoma transplants by treating animals with 
derivatives of N-diazoacetyl-glycine. This compound is an 
irreversible inhibitor of some proteolytic enzymes, but no 
experiments to identify the enzymes inhibited were reported. 
Turner and Weiss (1981) in a very detailed study of Lewis 
Lung carcinoma, showed aprotinin increased both spontaneous and 
experimental metastasis. Aprotinin is a broad spectrum protease 
inhibitor capable of inhibiting trypsin, plasmin, and also 
kallikreins. They also showed treatment with aprotinin after i.v. 
injection of tumor cells increased the retention of the tumor 
cells in the lungs and liver. This was suggested to be a result of 
inhibiting plasmin, which would allow a larger number of tumor 
cells to remain attached to the endothelium by a fibrin clot. A 
larger number of stably arrested cells would then give rise to a 
greater number of metastases. In contrast, Latner ~ ~. (1974) 
reported aprotinin inhibited tumor growth and metastasis of a 
malignant fibrosarcoma. Also, Giraldi ~~. (1977c) reported a 
significant inhibition of spontaneous metastasis of the Lewis Lung 
carcinoma following i.p. injection of aprotinin. Administration of 
leupeptin and pepstatin by the same protocol showed no effect, 
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which suggested the lack of an essential role of cathepsins B and 
D. Leupeptin, pepstatin, and antipain, also had no inhibitory 
effect on the spontaneous metastsis of hamster cells transformed 
by Human Herpes Simplex virus (Harvey ~.sJ..., 1977). Leupeptin was 
effective, however, in reducing by fifty percent the number of 
experimental metastasis of a hepatoma cell line in rats in 
experiments by Saito ~.aL (1980). In the same system, 
chymostatin and elastatinal had no inhibitory effect. The authors 
suggest that the reduction by leupeptin is due to an inhibition-of 
thrombokinase (Factor Xa), and histological examination of the 
lungs of animals treated with leupeptin prior to injection of 
tumor cells showed significantly fewer tumor cell thrombi. 
However, leupeptin inhibits cathepsin B 1000-fold more effectively 
than Factor Xa, and at the levels used in these experiments, 
leupeptin may be inhibiting other enzymes as well (see results and 
discussion). Therefore the mechanism of action of leupeptin in 
this system is unclear. It is again clear that protease inhibitors 
have produced different results, sometimes in seemingly identical 
systems. This may be due to differences in methods (i.e., Giraldi 
~ .aJ.... (1977c) used 200,000 KIU of aprotinin, compared to 5000 KIU 
used by Turner and Weiss (1981)), animal or tumor variations, and 
may depend on the stage of metastasis being examined. It may also 
be a consequence of the fact that the concentrations of the 
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inhibitors used have not been carefully monitored. It has been 
shown that proteinase inhibitors can be removed from circulation 
rapidly (Tanaka, 1983), and also that administration of some 
inhibitors may cause a compensatory overproduction of certain 
enzymes (Sutherland and Greenbaum, 1983; Aoyagi et .sJJ...., 1983; 
Tanaka~ .siJ....., 1984). Thus the time of the inhibitor injection may 
be extremely important in terms of the proteolytic status of the 
experimental animal. 
A different approach to studying protease production and 
metastasis has been used by Giraldi ~ s.J.... (1985a,b). In these 
experiments, animals bearing different tumors of varying 
metastatic potential were treated with proven cytotoxic or 
antimetastatic drugs. The levels of proteases (surface neutral 
protease, PA, cathepsin B) were assayed in the tumor before and 
after treatment. These experiments demonstrated no correlation 
between protease levels and metastases formation, nor did they 
reveal any correlation between inhibition of metastasis and 
inhibition of protease activity. These experiments do not directly 
test the role of proteases in metastasis. 
Recently nafazatrom, an antithrombotic compound (Bayer 6575) 
which was shown previously to be antimetastatic (Honn ~,al., 
1982), was shown to interfere with the degradation of endothelial 
matrix by B16 amelanotic melanoma (B16a) cells (Maniglia ~ .siJ....., 
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1986) • These experiments did not identify the enzymes responsible 
for degradation of the matrix. In addition, Maniglia ~.s.J... report 
that nafazatrom had no inhibitory effect on the ability of i.v. 
injected B16a cells to form lung colonies, indicating that the 
effect of nafazatrom on spontaneous metastasis was not due to its' 
antithrombotic properties. These results illustrate the difficulty 
involved in studying the complex process of metastasis. 
6. INHIBITORS USED IN THIS WORK 
Leupeptin, acetyl-Leu-Leu-Arginine-aldehyde, is often used as 
a general protease inhibitor in studies on metastasis. It has been 
shown to be nontoxic and has been shown to have potent J...n~ 
effects which correlate with its antiproteinase activity. For 
example, leupeptin has been used experimentally to treat 
pancreatitis (Jones ~.SlJ..., 1982), and 12 mg/kg three times a 
week was effective at preventing the onset of muscular dystrophy 
in a mouse model (Sher~ .SlJ..., 1981). Leupeptin is a tripeptide 
aldehyde in which the normally C-terminal carboxylic acid is 
converted to an aldehydic function (for structure, see Appendix 
A). This compound is a potent inhibitor of both serine and 
cysteine proteases with a primary specificity for arginine or 
lysine. The mechanism of inhibition by tri-peptide aldehydes has 
been shown to occur by a transition state analog process in which 
the active site nucleophile cs- or o-) forms a covalent bond with 
the aldehydic carbon (Kennedy and Schultz, 1979; Frankfater and 
Kuppy, 1981). This intermediate is partially stabilized by the 
forces which normally stabilize the proposed transition state, but 
cannot be cleaved to yield products because of the aldehyde 
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substitution. It can, however, dissociate to starting materials, 
so these tripeptide aldehydes are not irreversible inhibitors. It 
has also been shown that, even among proteases of identical 
primary specificity, altering the secondary or tertiary binding 
residues can have profound effects on the affinity of a protease 
for a particular tripeptide. For example, Bajuz ~.al_. (1978) have 
shown that compounds of the structure Phe-Pro-Arg have very high 
binding constants to thrombin, and as mentioned above, leupeptin 
has an extremely high affinity for cathepsin B. Studies on 
chloromethylketones demonstrated that sequences of the formula 
Glu-Gly-Arg were very effective at inhibiting UK (Coleman ~.al_., 
1979). However, chloromethylketones are toxic in..l!i.l!:.Q.. Patel~ 
~. (1983) have demonstrated by synthesizing various tripeptide 
aldehyde affinity resins that these peptides are capable of 
selectively binding a specific enzyme based on secondary 
specificity. Likewise, Kabi manufactures a series of tripeptide p-
nitroanilide substrates for many blood enzymes with a primary 
specificity for arginine which exhibit selectivity based on the 
other two residues chosen. Because of these features, i.e. low 
toxicity, high specificity, and potency as inhibitors, it may be 
possible to use these tripeptide aldehyde inhibitors in a model 
for metastasis to distinguish the roles of proteases implicated in 
metastasis. 
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Another inhibitor which was used in these studies, Ep453, was 
developed by Hanada ~ .slJ... (1983). A derivative of E-64, Ep453 is 
a peptide epoxide (for structure, see Appendix A) which is an 
irreversible inhibitor of cysteine proteases such as cathepsins B 
and L, and may also be used .1.nxiY.Q. to evaluate the roles of 
cysteine proteases in metastasis. 
MATERIALS AND METHODS 
MATERIALS 
Common chemicals and reagents were purchased from Sigma (St. 
Louis, MO) or Scientific Products (McGaw Park, Il). Leupeptin 
(acetyl-Leu-Leu-Argininal) was a gift of Dr. W. Troll (New York 
University Medical Center) or was purchased from Sigma 
(synthetic). D-Phe-Pro-Argininal, t-boc-D-Phe-Pro-Argininal, t-
boc-Glu-Gly-Argininal, and Glu-Gly-Argininal (trifluoroacetate 
salt) were all synthesized by members of Dr. R.M. Schultz's 
research group. Derivatives of E-64 (L-trans-epoxysuccinyl-
leucylamido(4-guanidino)butane) were a gift of Dr. W. Tanaka 
(Institute of Microbial Chemistry, Tokyo, Japan). Kabi substrates 
S-2251 (H-D-Val-Leu-Lysine-p-nitroanilide), S-2444 (pyro-Glu-Gly-
Arginine-p-nitoanilide), and S-2238 (H-D-Phe-Pipecolyl-Arginine-p-
nitroanilide), were purchased from Helena laboratories (Beaumont, 
TX). Human urokinase (Abbokinase, UK) was purchased from Abbott 
laboratories, (North Chicago, Il) and recombinant human tissue-
type plasminogen activator (rtPA) was a gift of Genetech (San 
Francisco, CA). Reagents for polyacrylamide gel electrophoresis 
were from Bio-Rad (Richmond, CA). Triton X-100 was from Kodak 
(Rochester, NY). All cell culture reagents were from Gibco (Grand 
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Island, NY) unless otherwise noted. Tissue culture flasks were 
from Corning Glass Works (Corning, NY) or Falcon (Oxnard, CA). 
Filter units were from Nalgene (Rochester, NY) and Millipore 
(Bedford, MA). Female C57BL/6 mice 6-8 weeks of age were purchased 
from Harlan Industries (Indianapolis, IN), Cumberland View Farms 
(Clinton, TN) or Charles River (Wilmington, MA) depending on 
availability. Animals were maintained by the Loyola University 
Medical Center Animal Research Facility under fully accredited 
(American Association for Accreditation of Laboratory Animal 
Care) conditions with unlimited food and water. 
~ CULTURE 
B16-F10 murine melanoma cells, obtained from the Frederick 
Cancer Center (Frederick, MD), were used for all experiments. This 
subline of the spontaneously arising B16 melanoma was derived by 
ten successive in Yi.Y.Q. cycles of i.v. injection into a lateral 
tail vein, isolation of tumor nodules growing in the lungs, growth 
in culture, and reinjection into animals (Fidler, 1973). Cells 
were cultured as adherant monolayers in Dulbecco's Modified Eagles 
Medium (DMEM) containing 10% fetal calf serum (FCS) and 100 U 
penicillin-100 mcg streptomycin per ml (complete media). Cultures 
were grown in humidified 5% co2- 95% air at 37° C in a Forma 
Scientific (Marietta, OH) water-jacketed incubator. All cell 
culture solutions were sterilized by filtration. Under these 
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conditions, the observed doubling time was about 16 hr, which 
agrees with published values (Fidler, 1975). Cells were routinely 
passaged when confluent using 0.25% trypsin (crude, porcine 
pancreas, Sigma) and 1mM ethylenediamine tetraacetic acid (EDTA) 
in phosphate buffered saline (PBS) (2 ml for one minute). Cultures 
usually contained about 10 million cells at this time and were 
split 1:30. Cells were cultured in 75 cm2 flasks in 10 ml of 
complete media. 
~COUNTING AND TRYPAN .lil&E.~ EXCLUSION~ lQB. ~ 
VIABILITY 
Cells were counted using an improved Neubauer hemacytometer 
(C. A. Hausser and Son, Philadelphia, PA). Cells were suspended in 
PBS and diluted to an appropriate concentration (approximately 1 x 
105). One drop of the cell suspension was placed in each chamber 
of the hemacytometer and the individual cells were counted with an 
Olympus (Tokyo) light microscope under a magnification of 100X. 
The number of cells in the original solution was calculated by 
multiplying the average of at least two determinations by the 
appropriate dilution factors. 
When making a determination of cell viability by the trypan 
blue dye exclusion test (Phillips, 1973), 1 ml of the cell 
suspension was mixed with 0.1 ml of a 0.4% trypan blue solution 
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and dispersed with a Pasteur pipette 10 times. A drop of this 
mixture was placed in the hemacytometer chamber. After 4 min the 
number of stained and unstained (viable) cells were counted, and 
the percentage viability determined. A minimum of one hundred 
cells were counted to determine viability. 
CRYOPRESERVATIQN .Qf. CELLS 
Semiconfluent cultures of B16-F10 cells were used to prepare 
frozen samples for storage. Flasks containing 2-6 x 106 cells were 
harvested using a 0.25% trypsin and 1mM EDTA in PBS wash for 1 
min, followed by addition of 5 ml complete media to inactivate the 
trypsin. Cells were collected by centrifugation (!EC clinical 
tabletop) at 2500 x g for 3 min in sterile 15 ml polystyrene tubes 
(Corning Glass Works, Corning, NY). The cell pellet was then 
resuspended by gentle pipetting in 1 ml freezing media (DMEM 
containing 20 % FCS and 10% dimethylsulfoxide at o° C) and 
pipetted into a sterile 2 ml cryotube (Nuno, Vangard Int., Inc., 
Neptune, NJ). The cryotube was sealed, wrapped in paper towels, 
placed inside a styrofoam container and placed into a -20° C 
freezer for 12-16 hr. The container was then placed into a -80° C 
freezer for an additional 12-16 hr. Following this slow freezing 
procedure, the cryotubes were placed into a liquid nitrogen 
storage tank. Several flasks of cells were frozen at the same 
time, and after at least three days, one or more of the frozen 
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samples were thawed and tested for viability. This was done by 
thawing the frozen cryotube rapidly by immersion in a 37° C 
waterbath for several min. The cell suspension was then mixed with 
5 ml of complete media warmed to 37° Cina 15 ml tube and 
centrifuged as above. This procedure removes excess DMSO. The cell 
pellet is then resuspended in several ml of complete media and 
added to a flask containing 10 ml complete media. This procedure 
always resulted in a confluent culture of cells in two days or 
less, indicating that the frozen cells were highly viable. Because 
there are reports that B16 melanoma cells are phenotypically 
unstable, after periods of 1-5 months, all growing cultures were 
discarded and a sample of frozen cells was removed from storage 
and used to initiate new cultures. 
EXPERIMENTAL METASTASES 
The effect of the protease inhibitors on metastases was 
assesed utilizing the B16 melanoma model for experimental 
metastasis as described by Fidler (1978) and outlined below. 
Briefly, 2-3 x105 B16-F10 cells were seeded in 10 ml of 
complete media. After three days, the semi-confluent cells were 
collected by a mild trypsinization, washed in complete media, 
resuspended in PBS, counted and diluted to 500,000 cells/ml. 
Originally the cells were kept at room temperature; in later 
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experiments the cells were placed in a sterile septum tube and 
kept on ice to improve viability. Cells treated in this way were 
always greater than 85% viable by the trypan blue exclusion 
method, and were often used to initiate cultures AFTER all the 
mice had been injected with no apparent decrease in viability. 
Female C57BL6 mice 6-8 weeks old were obtained from Harlan, 
Cumberland View Farms, or Charles River. For tumor cell 
innoculation, the mice were placed (in their cages with access to 
water) under a 150 watt light bulb until their tail veins were 
clearly dilated (approximately 15 minutes). Individual animals 
were removed alternately from the control and treated group and 
gently placed in a small dish-washing basket with their tails 
drawn through an opening in the side of the cage. This insured 
that each group of animals received injections of cells which had 
been in suspension for equal time. The tail was swabbed with 70% 
ethanol in water, straightened across a cork the same height as 
the tail, and 0.2 ml of the cell solution (containing 100,000 or 
500,000 cells per ml) was injected slowly into the lateral tail 
vein. A 0.25 ml glass syringe was used for the injections with a 
clean 27 gauge 0.5 inch needle used for each animal. An injection 
was considered successful when there was no resistance to the 
injection. Any animals which showed blebbing of the skin or 
struggled excessively were eliminated from the study. The number 
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of animals successfully injected varied between experiments, but 
averaged about 70%. The cell suspension was inverted repeatedly 
during the experiment, and microscopic examination or the cell 
suspension after the conclusion of the injections revealed no cell 
clumping. Animals were sacrificed after 15 or 21 days, the lungs 
were removed, rinsed in PBS, dissected into lobes, and the tumor 
colonies were counted under a 30X binocular dissecting scope. Only 
surface colonies were counted on both sides of the lung lobes. 
Because of the presence of melanin, the black melanoma colonies 
were easily distinguishable. When amelanotic colonies were 
present, lungs were dissected as above and stained overnight with 
Bouins solution (250 ml formalin, 750 ml saturated picric acid, 5 
ml glacial acetic acid) before counting. This staining procedure 
colored the normal lung tissue yellow, while leaving the tumor 
nodules white so that they could be counted. Electron microscopy 
was performed (Dr. Persky, Loyola University Medical Center) on 
amelanotic nodules and the presence of stage III pre-melanosomes 
was taken as conclusive proof that the cells forming the nodules 
were melanomas (see Appendix C). Results were analysed by the 
Students t-test and Mann-Whitney U test (Colton, 1974). Autopsies 
were routinely performed on animals from the different 
experiments. Internal organs, subcutaneous sites, and popliteal 
lymph nodes were grossly examined. 
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TREATMENT OF m_ Hlll! PROTEASE INHIBITORS 
Protease inhibitors were introduced into mice by the 
following procedures in order to determine their effect on the 
process of experimental metastasis. Treatment with the protease 
inhibitors was always begun before injection of the tumor cells. 
All protease inhibitor solutions were sterilized by filtration. 
When protease inhibitors were introduced by repeated i.p. 
injection, the animals received injections 12 hr apart for a total 
of 13 injections. The tumor cells were injected 1 hr following the 
second injection of inhibitor. Using this protocol, animals 
received the following protease inhibitors and dosages in separate 
experiments: leupeptin at 5, 25, 37.5, or 50 mg/kg in 0.2 ml PBS; 
t-boc-D-Phe-Pro-Argininal at 12.5, 25, or 37.5 mg/kg in 0.2 ml 
PBS; D-Phe-Pro-Argininal at 37.5 mg/kg in 0.2 ml 5% DMSO, 10% 
ethanol, 85% PBS; Ep453 at 50 mg/kg in 0.05 ml DMSO. Animals 
treated with the UK inhibitor t-boc-Glu-Gly-Argininal received 8 
injections of 30 mg in 0.2 ml PBS over a 36 hr period 
(approximately every 4 hr) beginning 1 hr before the tumor cell 
injection. Animals treated with the UK inhibitor (tfa)Glu-Gly-
Argininal received 8 injections of 30 mg in 0.2 ml PBS over a 25 
hr period (approximately every 3 hr) beginning 1 hr before the 
tumor cell injection. In all experiments, control animals received 
equal volumes of the drug vehicle by the identical schedule. 
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When osmotic pumps were used to deliver the protease inhibitor 
solutions, the pumps were implanted (see below) at least 12 hr 
before the tumor cell injection. The solutions loaded in the pumps 
in separate experiments were as follows: leupeptin, 0.1 M in PBS; 
Ep453, 0.08 M in propylene glycol; D-Phe-Pro-Argininal, 0.25 M in 
40% DMSO, 60% PBS. All control animals were implanted with pumps 
containing the drug vehicle. The pumps contained a minimum of 200 
ul of protease inhibitor solution and administered the solution to 
the animals at a flow rate of 1 ul/hr. 
IMPLAHTATION.Q[OSMOTIC PUMPS 
When osmotic mini-diffusion pumps (Alzet, Model 2001) were 
used to deliver protease inhibitor solutions, they were implanted 
according to the manufacturers instructions as described below. 
The mice were anesthetized with an i.p. injection of 0.2 ml 
pentobarbital solution (6.5 mgs./ml PBS) and their backs were 
shaved. The area was swabbed with Betadine (povidone-iodine 10%, 
Purdue Frederick Co.) solution and a small incision was made 
through the skin. A subcutaneous tunnel was formed using blunt 
forceps, and the pump was inserted towards the animal's head. The 
opening was then closed with two 9 mm wound clips. Occasionally, 
when the skin was pulled tight around the pump, the wound would 
reopen to the sides of the wound clips. In these cases, the animal 
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was anesthetized again and the wound repaired. Pumps were removed 
by reversal of these procedures after delivery of the drug was 
complete. The pumps were handled with sterile gloves and none of 
the mice showed any sign of infection or discomfort. 
ASSAY .Q!".. PROTEASE INHIBITOR CONCENTRATIONS llf.IIYQ. 
In order to determine the .1.n.~ concentrations of the 
protease inhibitors, the serum levels of the inhibitors were 
measured by the following procedures. 
Mice were injected i.p. with the protease inhibitor solution 
to be tested and sacrificed at selected time points by co2 
suffocation. Alternatively, mice were surgically implanted with 
osmotic pumps and were sacrificed on days 1-5 after the 
implantation. Blood samples (approximately 1 ml) were collected 
immediately by cardiac puncture after surgically opening the rib 
cage to expose the heart. Blood was collected using a 22 gauge 
needle, allowed to clot, and centrifuged in an Eppendorf microfuge 
for 15 minutes at 4° C. The serum was collected, diluted (usually 
1:2 depending on the sample size) with the buffer used in the 
enzyme assay, and filtered through an Amicon YM-5 membrane (5,000 
Mwt. cut-off) using the Amicon Micropartition system to remove 
serum protein inhibitors. The filter units were centrifuged for at 
least 30 minutes in a clinical tabletop !EC centrifuge at 2500 x g 
at 4°. A sample of the filtrate (usually 200 ul) was assayed for 
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the presence of the injected protease inhibitor by incubating for 
3 minutes with enzyme-buffer solution and then adding the 
appropriate p-nitroanilide substrate. The rate of hydrolysis of 
substrate was monitored at 405 nm in a Perkin-Elmer 
spectrophotometer at 25° C and compared to the control rate 
obtained using serum from mice treated with only the drug vehicle. 
Leupeptin and Ep453 were assayed by their ability to inhibit 
papain. Papain, 100 ul of 2.8 x 10-6 M which was activated by a 30 
minutes incubation in an equal volume of 30 mM dithioerythritol-
15mM EDTA at pH 5.2, was mixed with the serum sample to be assayed 
and enough 0.3 M Na citrate/phosphate buffer pH 6.2 to bring the 
total volume to 1.1 ml. After addition of 30 ul of a 1 mg/ml 
solution of N-benzoyl-arginine-p-nitroanilide (BAPNA), the rate of 
hydrolysis was measured. For the assay of tFA- and t-boc Glu-Gly-
Argininal compounds, the hydrolysis of 10 ul of 5 x 10-4 M S-2444 
by urokinase (1.5 I.U. UK) was observed in a total volume of 315 
ul 0.1 M Tris-0.1 M NaCl pH 7.8 containing 0.1% Triton-I 100 and 
the sample to be tested. The thrombin inhibitors t-boc- and H- D-
Phe-Pro-Argininal were assayed against thrombin (20 mU bovine 
thrombin (Pentax)) in a total volume of 1.160 ml 0.2 M P04 buffer 
pH 8.0 containing 50 ul 1 x 10 -3 M S-2238 and the serum sample to 
be tested. Concentrations of inhibitors were estimated by 
comparison to rates obtained with known amounts of inhibitor 
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added. 
COLLECTION .Q[ SERUM-FREE CONDITIONED MEDIUM 
For studies of the secreted B16 melanoma plasminogen 
activators, cells were seeded in 75cm2 or 150cm2 flasks containing 
10 or 25 ml complete DMEM. When semi-confluent, the media was 
removed and the cell surface was washed twice with 4-5 ml PBS, 
after which the flasks were reincubated with 10 or 25 ml of the 
same media without serum (serum-free medium, SFM). After 24 hours, 
the serum-free conditioned medium (SFCM) was collected and the 
cells were reincubated for a second 24 hour period. The SFCM was 
again collected, after which these flasks were discarded. 
Sometimes media was collected for a third day if the cell layer 
was still attached and morphologically healthy by microscopic 
examination. If the cells were heavily confluent, incubation in 
SFM often resulted in sheets of cells releasing from the dish, and 
this media was always discarded. Variations to try to improve the 
yield and efficiency of this procedure, such as selection 
procedures to develop a cell line which would be maintained in SFM 
or recycling of cell cultures after a passage in SFM, and the use 
of serum supplements (Ultroser G., LKB) were attempted. However, 
none of these attempts proved fruitful (see Appendix B). After 
collection of the SFCM, it was centrifuged at 6000 rpm and the 
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supernatant was frozen at -20° C until further study. In recent 
experiments, the SFM (Sigma) was supplemented with 4.5 g glucose/L 
to increase the nutritional properties of the SFM and/or 30 KIU/ml 
of aprotinin (Sigma) to inhibit proteolytic degradation of the 
plasminogen activator. 
PLASMINQGEN ACTIVATOR ASSAYS 
Three separate assays were used for determining PA activity. 
The first measures the ability of PA to produce zones of lysis on 
a fibrin-agar substrate by activating plasminogen, and was 
performed essentially as described by Lassen (1953). Agar (Kodak) 
2.5% with 0.02% NaN3 added to inhibit microbial growth was 
prepared by autoclaving and then aliquoted into sterile 15 ml 
plastic tubes (Corning), capped and stored at room temperature. 
Human plasminogen (Worthington) was dissolved in PBS at an initial 
concentration of 10 mg/ml and then treated with DFP (Aldrich) to 
inactivate plasmin. Solutions of plasminogen were incubated for at 
least one hour with DFP at a final concentration of 25 mM and then 
assayed using S-2251. This treatment was repeated until the 
plasmin activity could no longer be detected, and the solution was 
then dialysed against PBS, aliquoted into plastic tubes (5 ml 
polystyrene, Sarstedt) and frozen at -20° C until use. Fibrinogen 
(Bovine type IV, Sigma ) was originally further purified (Laki, 
1951; Mosesson, 1962), but this was found to be unnecessary. A 10 
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mg/ml fibrinogen solution in PBS containing 0.02% NaN3 was used. 
Bovine thrombin (Pentex, Miles laboratories) was dissolved in 0.9% 
NaCl and frozen at -20° C in 1 ml fractions each containing 100 
IU. For preparation of fibrin-agar plates, a tube of 4 ml agar was 
heated in a boiling water bath until melted. This was placed in a 
heated water bath at 45° C. To this tube was added 0.8 ml of PBS 
with 0.02% NaN3 or 0.8 ml of plasminogen solution also at 45° C 
and 37 ul thrombin solution. The tube was inverted and then 2.5 ml 
fibrinogen solution was rapidly added, the solution inverted, and 
poured smoothly unto a petri dish (diSPo, sterile polystyrene, 10 
x 1.5 cm, Scientific Products) which was warmed to 45° C by 
floating in the water bath. The dish was placed on a level surface 
and allowed to harden. For controls, it was found to be most 
convienant to pour the fibrin agar plate without adding 
plasminogen and then heating the plate to 80° c for 40-50 minutes 
(Lassen, 1953). This procedure denatured the contaminating 
plasminogen without affecting significantly the ability of plasmin 
or trypsin to degrade the fibrin. When plasminogen activators were 
present in the sample, they produced active plasmin which degraded 
the fibrin layer and resulted in clear zones of lysis. This test 
was not used qauntitatively, but verified the presence of 
plasminogen activator activity. Plates varied in their stability 
but could usually be observed for 3-4 days before non-specific 
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lysis from contamination appeared. 
The second assay used involved measuring plasminogen 
activation by measuring the rate of hydrolysis of S-2251 by the 
active plasmin formed. In this assay 100 ul of plasminogen 
solution was added to 1 ml of 0.05 M Tris pH 8.8 and 25 ul of S-
2251 (2.5 mg/ml H20). Absorbance was followed at 405 nm in a 
Perkin Elmer specrophotometer for several minutes to observe any 
backgound rate. The reaction was then repeated using a sample of 
the solution to be tested for PA activity and enough buffer to 
make the volumes equal, and the acceleration in rate was observed. 
Alternatively, the PA sample was added directly to the mixture and 
the acceleration was observed. 
Finally, the urokinase-specific substrate S-2444 was used to 
assay the presence of UK-like enzymes and to determine inhibition 
constants. Generally, these assays involved mixing the sample (100 
ul) to be tested in enough 0.05 M Tris buffer pH 8.8 to bring the 
volume to 1.1 ml. Substrate was then added (25 ul of S-2444, 5 x 
10-3 M) and the rate of hydrolysis was measured at 405 nm in a 
Perkin-Elmer spectrophotometer (Hitachi, Ltd., Tokyo, Japan). When 
using samples prepared from B16 melanoma cell cultures, this assay 
was usually done in the presence of 30 KIU per ml of aprotinin to 
inhibit other trypsin-like proteases which may have been present. 
Aprotinin does not affect PAs at this concentration (Dano ~.al., 
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1985). 
PURIFICATION .Qf.IUQ. PLASMINOGEN ACTIVATOR 
The purification procedure described here was the final 
procedure used to prepare samples for the experiments described, 
although various modifications were attempted. This procedure was 
based on that of Dano~~. (1980). SFCM was thawed and adjusted 
to pH 5.5 with acetic acid, made 0.1 % in Tri ton X-100, and 0.01 M 
in ZnC12• This was applied at a flow rate of 1 ml/min to a DEAE 
Sephadex-A25 (Pharmacia) column (5-7 x 2.5 cm.,Biorad) coupled to 
a p-aminobenzamidine affinity resin (Pierce, -aminocaproic acid 
spacer on agarose, 5-10 x 1 cm.) in the cold. The columns were 
equilibrated with 0.01 M acetate pH 5.5, containing 0.1% Triton 
X-100, 0.2 M NaCl, 0.01 M ZnC12• After the sample had been 
applied (usually 500-1000 ml), the columns were washed with the 
equilibration buffer until absorbance reached baseline or until 
the red dye of the media was eluted. The columns were then 
disconnected and the benzamidine column was washed with the same 
buffer made 0.5 M in NaCl (until baseline reached zero or at least 
10 column volumes). The bound plasminogen activators were then 
eluted using 0.5 M arginine in 0.01 M acetate, 0.1% Triton X-100, 
0.01 M ZnC12, pH 5.5 (usually 50-100 ml). This solution was then 
concentrated under N2 pressure using an Amicon PM10 filter in an 
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Amicon stirred ultrafiltration device kept in an ice bath. If 
necessary, buffer exchanges were performed by repeated cycles of 
dilution and dialysis using the same system. Earlier variations of 
this procedure were performed at room temperature or were 
performed without addition of ZnC12, and eluates were concentrated 
by lyophilization. 
IRREVERSIBLE INHIBITION .Qf:1ll.Q. PLASMINOGEN ACTIVATOR 
For the DFP and p-chloromercuribenzoate (pCMB) inhibition 
studies, 200 ul of 0.05 M Tris-.025 M EDTA pH 8.8 was mixed with 
150 ul of a partially purified PA preparation. After addition of 
either 30 ul DFP (135 mM in isopropanol), 30 ul isopropanol, or 30 
ul pCMB (277mM in H20) these solutions were incubated for 30 min 
at room temperature. 300 ul of each solution were then assayed 
against S-2444, and 50 ul were assayed in the plasminogen-S-2251 
coupled assay. Residual DFP was inactivated by incubation of the 
enzyme sample with buffer before the plasminogen activation assay 
was performed, and this was verified by showing that the 
plasminogen could be activated by urokinase. 
DETERMINATION .Qf: INHIBITION CONSTANTS 
For inhibition studies of rtPA, a 0.1 mg/ml solution in 0.01 
M acetate, 0.1% Triton X-100, 0.2 M NaCl, pH 5.5, was used. To 
100 ul of this solution was added the inhibitor solution and 
enough 0.05 M Tris-0.2 M NaCl pH 8.8 to bring the total volume to 
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1.075 ml. After a 3 minute incubation, 25 ul of S-2444 (final 
concentration 1.1 x 10-4 M) was added, the cuvettes were inverted 
three times, and the rate of absorbance change was followed at 405 
nm in a Gilford Response or Perkin-Elmer recording 
spectrophotometer for the initial 30 minute period. All inhibitors 
were tested at at least two different concentrations, and each was 
performed in triplicate. Stock solutions of inhibitors were made 
up as follows: tfa-Glu-Gly-Argininal, t-boc-Glu-Gly-Argininal, and 
leupeptin were dissolved at 1 mg/ ml in 0.05 M Tris-0.2M NaCl, pH 
8.8; D-Phe-Pro-Argininal, 3. 7 mgs. in 1.875 ml Tris containing 25 
ul DMSO; t-boc-D-Phe-Pro-Argininal, 2.4 mgs in 1.6 ml Tris 
containing 0.6 ml DMSO; DNS-Glu-Gly-Argininal, 4.4 mgs in 1.025 ml 
Tris containing 25 ul DMSO. When necessary, inhibitor solutions 
were diluted in Tris buffer ( 0.5 M, pH 8.8). 
Kis were calculated by the equation below where (I) = the 
inhibitor concentration, vu = the rate in the absence of inhibitor 
and v1 = the rate in the presence of the inhibitor. These 
experiments were performed under first order conditions with 
substrate < Km. 
(I) 
- 1 
r 
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Inhibition constants against partially purified B16 melanoma 
PA and concentrated SFCM were estimated in essentially the same 
way, except for the partially purified preperation, the Tris 
buffer contained 0.25 M EDTA to remove any remaining zn++, and the 
reaction times were 60 and 100 minutes respectively, due to the 
lower enzyme concentration. 
POLYACRYLAMIDE ~ ELECTROPHORESIS 
Discontinuous sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed to determine the purity 
and molecular weights of plasminogen activators in samples 
prepared from the B16 melanoma by comparison to standards of known 
molecular weight. The procedure was that of Laemmli (1970) as 
detailed by Crowe ~.£\l... (1978). All electrophoresis equipment and 
reagents were from Bio-Rad (Richmond, CA). Gels were 16 x 18 cm x 
0.75 cm thick and were composed of a stacking gel (4-5 cm) of 3% 
acrylamide and a resolving gel of 11% acrylamide. Electrophoresis 
was performed at 25 mA for 6 hr or at 10 mA for 14-16 hr in a 
running buffer of 0.025 M Tris, 0.192 M glycine pH 8.3 containing 
1% SDS. Acrylamide stock solution (30% acrylamide-0.8% 
bisacrylamide in distilled water) was filtered through Whatman 
(Clifton, NJ) fluted paper and stored in the dark at 4° C. The 
lower gel buffer was 1.5 M Tris pH 8.8 containing 0.4% SDS and the 
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stacking gel buffer was 0.5 M Tris pH 6.3 containing 0.4% SDS. 
Polymerization was initiated by the addition of 75-150 ul of 10% 
ammonium persulfate and 10 ul of N,N,N',N'-
tetramethylethylenediamine. Samples for electrophoresis were 
diluted 1:1 in sample buffer (sample buffer contained: 10 ml 
glycerol, 23 ml SDS (10%), 2 ml bromphenol blue (0.1%), 8.3 ml 
stacking gel buffer, 6.7 ml H2o). Protein molecular weight 
standards (Bio-Rad, Richmond, CA) were as follows: lysozyme, 
14,400; soybean trypsin inhibitor, 21,500; carbonic anhydrase, 
31,000; ovalbumin, 45,000; bovine serum albumin, 66,200; 
phosphorylase B; 92,500. Gels were stained in 46% methanol, 8% 
glacial acetic acid, 0.1% Coomassie Blue (500 ml). Gels were 
destained in several washes (250 ml) of 20% methanol-8% glacial 
acetic acid. 
VISUALIZATION .Q[ PLASMINOGEN ACTIVATORS ~ ZYMQGRAPHY 
When gels were overlayed on fibrin-agar plates to visualize 
the position of PAs, the procedures of Granelli-Piperno and Reich 
(1979) were followed as detailed by Crowe ~ .sl_. (1978). This 
procedure consisted of running the samples on SDS-PAGE under the 
usual conditions (see above), but instead of fixing and staining, 
the gel was soaked in a 2.5% v/v solution (250 ml) of Triton-X 100 
for at least 1 hour, with gentle agitation. This replaces the SDS 
with Triton X-100 and allows the PAs to regain enzymatic activity. 
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This gel is then rinsed in dH20 and carefully overlayed on a 
fibrin-agar substrate prepared in a petri dish as described above, 
only in a 10cm square dish (Lab Tek) using double the amount of 
solutions. The plate was then incubated at 37° C in the humidified 
cell culture incubator. When plasminogen activators were present 
in the electrophoresis gel, they diffused into the fibrin-agar 
substrate and activated plasminogen to plasmin. The plasmin then 
produced clear bands of lysis which allowed the positions of 
plasminogen activators in the original electrophoresis gel to be 
determined. 
ANTIBODY STQDIES 
Goat anti-human tPA and goat anti-human UK IgG antibodies 
were purchased from American Diagnostica (batch #s 8312/0105 and 
8412/12). 5 mgs of each were reconstituted in 1 ml of sterile 
filtered 0.05 M Tris pH 8.8 and mixed well. Each antibody solution 
(15 ul) and 15 ul of Tris were added to 15 ul of the purified PA 
preparation in individual microcentrifuge tubes and vortexed. 
Tubes were incubated for 3.5 hours at room temperature, and then 
10 ul of each solution was spotted in wells punched on a fibrin 
agar plate, in duplicate. The fibrin agar plate was then incubated 
at 37° C and examined regularly over the next 5 days for signs of 
lysis. 
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PROTEIN DETERMINATION 
Protein was determined by the method of Lowry (1951) or by 
using the Pierce BCA reagent and comparing to standard curves. 
When Triton X-100 was present in the Lowry assay, SDS was added at 
a concentration which would prevent precipitation (Bonsall and 
Hunt, 1971). 
RESULTS 
SELECTIVITY OF TRIPEPTIDE ALDEHYDE INHIBITORS 
Peptide aldehydes have been synthesized with sequences 
designed to inhibit proteolytic enzymes implicated in the 
metastatic process. The enzymes chosen for investigation in this 
study were cathepsin B, thrombin, and urokinase. The peptide 
aldehydes, t-boc-D-Phe-Pro-Argininal, D-Phe-Pro-Argininal, (R-D-
Phe-Pro-Argininals), (tfa)Glu-Gly-Argininal, t-boc-Glu-Gly-
Argininal, (R-Glu-Gly-Argininals), and leupeptin, were tested for 
their ability to inhibit the selected proteases believed to play a 
role in metastasis. From the determined Ki values in Table 1, it 
is clear that leupeptin is an extremely potent inhibitor of 
cathepsin B. The Ki of leupeptin for cathepsin B of approximately 
4 x 10-9 M indicates that leupeptin is an extremely potent 
inhibitor of cathepsin B. Likewise the Ki's of the R-D-Phe-Pro-
Argininal compounds against thrombin of 10-8 M show that these 
compounds should be able to effectively inhibit the activity of 
thrombin .1.n. ~ The Ki values of the R-Gly-Gly-Argininal 
compounds for UK are higher than those of the thrombin and 
cathepsin B inhibitors, but they are still selective for UK (see 
below). By using higher concentrations they should still be 
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Table 1. Inhibition constants of tripeptide aldehydes 
against proteinases implicated in the metastatic process (from 
Ostrowski tl .s.l..., 1986). 
!nh1b1t1on Constan.t.1. 2I.. Peptidyl Aldehydes Against Selected Protease Enzyme3 
Enzym~ '1• H. 
Ac-Leu-Leu- D-Phe-Pro- Boc-D-Phe-Pro- Glu-Gly- Boc-Glu-Gly-
Arg1a1nal Argininal Argininal Argininal Argin1nal 
Thrombin ll. 7x10·6 1.1:110-8 1.5x10·8 >2x10·ll >2x10-4 
Factor Ia 5.1x10-6 s.2x10·5 3.9:110-6 >2x10·ll 3.1:110·4 
Urokinase 7.1:110-5 2.ox10·11 2.2:110-6 2.1:110-5 5.4x10·5 
Plasmin 1.ex10·6 2.6x1 o-5 2.6x10-6 >2:110-ll 1.6x10·4 
Cathepsin B 3.7x1o-9 >2x10-s >2x1o-5 >2x10·5 
-I 
w 
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effective at inhibiting UK in an .in.Y1.Y.2. model for metastasis. 
As mentioned previously, leupeptin can also inhibit other 
enzymes believed to be involved in metastasis. Thus the Ki values 
of leupeptin against thrombin, UK, factor Xa, and plasmin were 
also determined. These are given in Table 1. The Ki value which is 
closest to that of cathepsin B was obtained for plasmin (2 x 10-6 
M). The ratio Ki plasmin I KI cathepsin B is indicative of the 
specificity of leupeptin and shows that leupeptin is approximately 
500-fold more effective at inhibiting cathepsin B than plasmin.· 
This selectivity of leupeptin is even greater for the other 
enzymes proposed to be involved in metastasis. Likewise, D-Phe-
Pro-Argininal has a Ki plasmin I Ki thrombin of approximately 250. 
The R-Glu-Gly-Argininal compounds were not as effective at 
inhibiting UK and therefore their specificity ratio was about an 
order of magnitude over the other proteases. However, these 
compounds still were selective for UK. 
EFFECT .Qf'.. CATHEPSIN ll INHIBITORS .QN. METASTASIS 
An attempt to inhibit experimental metastasis with leupeptin 
was made in a manner similar to that used by Saito ~.al. (1980). 
In these experiments, leupeptin at a concentration of 50 mg/kg in 
0.2 ml PBS was injected i.p. into one group of mice while the 
control group received an equal volume of PBS. Mice were injected 
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with the drug solutions thirteen times, once every 12 hours. 
Tumor cells, (100,000) were injected into the lateral tail vein of 
each animal approximately 1-3 hrs. after the second drug 
injection. As shown in Table 2, experiment 1, the leupeptin 
treated group showed a significant reduction in the number of 
metastatic lung colonies (by Student's t-test). This agrees with 
the results of Saito ~.al. (1980) who also observed a 50% 
reduction in lung colonies using the same protocol with a hepatoma 
cell line in rats. However, further experiments with leupeptin 
failed to yield significant inhibition (as analysed by Student's 
t-test for differences about a mean and the Mann-Whitney U test). 
This can be seen in Table 2 experiments 2-7. It will be noticed 
that in each case, except experiment 7, leupeptin produced a 
decrease in the average number of lung colonies. (In experiment 7 
the colonies had grown so large that an accurate count was 
difficult. At this time, the criteria used in counting resulted 
in a minimal number, so that two or more colonies which had grown 
together were counted as one, possibly resulting in the decrease 
compared to the leupeptin treated group. In future experiments, 
the time before sacrifice was shortened to avoid this problem and 
the maximal number of metastases were determined). However, in 
only the first experiment was this difference significant. It is 
interesting to note that in experiments 2, 3, and 5 (Table 2) 
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Table £ 
Effect of i.p. Injected Leupeptin on Experimental Metastasis 
Experimental Number of Lung Metastases Mean 
Treatmenta per Animal (±s.E.) 
1. 
Control 13,17,21,21,37,47,51 30.±6 
Leupeptin (50) 0,7,10,15,17,18,22,31 15±3b 
2. 
Control 66,68,69,88,108,180 97±18 
Leupeptin ( 5) 32,38,66,72,83,125,146 8o±16 
Leupeptin ( 50) 26,32,36,46,69,111,168 7o±20 
3. 
Control 3,8,18,22,25,41,54,60,70, 
73,84,92,120,133,299 74±19 
Leupeptin ( 5) 4,12,14,18,28,33,47,66,70, 
76,77,79,81,86,101,106,120 6o±g 
4. 
Control 1,23,33,41,54,59,121 47±14 
Leupeptin (50) 5,6,23,44,103 35±18 
5, 
(20,000 cells) 
Control o,o,o, 1, 1, 1,9, 10, 10 3.6±1,5 
Leupeptin (25) 0,0,0,1,1,1,1,3 o.g±o.4 
6. 
Control 1, 3, 8 4±1.8 
Leupeptin ( 5) 0,1,2,2,5 2±o.8 
Leupeptin (50) 0,1,1,5 1. 8±1. 1 
7, 
Control 5,6,6,14,15,20,21,36,36,41,60 24.±.s 
Leupeptin (37,5) 0,10,18,22,28,39,40,43,44, 
49,54 32.±.s 
aNumbers in ( ) indicate mg/kg injected i.p. every 12 hours for 
6·5 days. Control animals received injections of drug vehicle. 
Value is significantly different from control by Student's t-
test at P < 0.05. 
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where different amounts of tumor cells were injected (20,000) or 
lower amounts of leupeptin (5 or 25 mg/kg) were used, this trend 
continued. 
To verify this lack of a statistical reduction in 
experimental metastasis using a strong cathepsin B inhibitor, the 
peptide epoxide Ep453 was used to treat mice in the same fashion 
as leupeptin. In plasma, the Ep453 is rapidly converted to the 
more soluble compound Ep475 by esterases (Hanada ~ .sJ..., 1983). 
This conversion occurs in less than 30 minutes (Ostrowski ~.al.., 
1986), and the Ep475 produced is a potent, irreversible inhibitor 
of cathepsins and other cysteine proteases. Again, the inhibition 
of cathepsin B by this procedure produced no reduction of 
metastasis as shown in Table 3. 
Although this protocol has been shown to reduce metastasis in 
other systems, the possibility that the dose of leupeptin used was 
not sufficient to inhibit cathepsin B in this model must be 
considered. Previous data has shown that leupeptin has a short 
halftime J..n..Y.1.YQ. (a halftime of 12 minutes has been reported, 
Tanaka, 1983), although lower doses than that used here have had 
lasting effects on dystrophy (see literature review). In an 
attempt to determine if the dosage used was sufficient to inhibit 
cathepsin B, the blood levels of leupeptin were determined by the 
procedure detailed in the methods section. As shown in Table 4, 
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Table 3. 
Effect of i.p. Injected Ep453 on Experimental Metastasis 
Experimental 
Treatment a 
Control 
Ep453 (50) 
Number of Lung Metastases 
per Animal 
15,31,44,46,48,54,97,113,131,139,142 
8 '36, 37 '42, 42 '51 '60, 60 '80' 127' 129' 
153,180 
Mean 
(±. S.E.) 
aNumber in ( ) indicate mg/kg injected i.p. every 12 hours for 
5.5 days. Control animals received injections of the drug 
vehicle. 
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Table .!!. 
Turnover of Leupeptin in Mouse Plasma 
following i.p. Injectiona 
Time {hours) Leupeptin cone. {M) 
0.5 4.9 x 10-5 
1. 0 3.67 x 10-5 
2.0 1.54 x 10-5 
4.0 2.52 x 10-7 
aMice were sacrificed at the indicated times after an i.p. 
injection of 50 mg/kg of leupeptin and serum levels of the drug 
were determined as described in methods. 
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leupeptin is originally present at very high levels (5 x 10-5M) 
following the injection. At this level, leupeptin will inhibit 
all of the proteases possibly involved in metastasis which were 
targeted for study (Table 1). After 6 hr, the level of leupeptin 
was below the limit of detection in this assay, but may have still 
been present in amounts capable of inhibiting cathepsin B. 
Although the evidence still argues strongly against a role of 
cathepsin B, an alternative method of drug delivery was used to 
further test this hypothesis. 
In the following experiments (Table 5), leupeptin was 
delivered by continuous infusion using Alzet mini-osmotic pumps. 
The pumps were loaded with an amount of leupeptin equivalent to 
that delivered by injections, and the determination of the blood 
level of leupeptin showed a steady level of 3 x 10-6M for at least 
5 days. In the first experiment (Table 5) only a small number of 
animals were tested, and although the variation is quite large, 
there was no significant reduction of metastases in the leupeptin 
group. This experiment was repeated twice using larger groups of 
animals (Table 5, experiments 2 and 3). Again no significant 
difference in the number of metastases was observed between the 
control and the leupeptin treated animals. 
The peptide epoxide (Ep453) was also infused continuously by 
osmotic pump to see the effect of a second potent inhibitor of 
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Table .5.. 
Effect of Continuously Infused Leupeptin On Experimental 
Metastasis 
Solution 
Infused a 
1 • 
Control (PBS) 
Leupeptin 
( 0. 1 M in PBS) 
2. 
Control (PBS) 
Leupeptin 
( 0 • 1 M in PBS) 
3, 
Control (PBS) 
Leupeptin 
( 0. 1 M in PBS) 
Number of Lung Metastases 
per Animal 
43,47,>300,>300 
7, 15,29,222 
34,46,64,71,80,96,111,132, 
133,153,157,236 
74,91,102,109,109,121,127, 
137,155,250 
1,2,2,3,4,4,5,6,7,7,7,7,8,8,10 
0,0,1,2,2,3,4,6,20 
Mean 
(± S.E.) 
1og±16 
------------------------·---- - -- --- --
asolution in () infused into animal from Alzet mini-osmotic pumps 
surgically implanted into mice. Rates of infusion were 1 uL/hr 
over 5 to 7 days. Steady-state concentration of leup1ftin in 
mouse plasma during infusion of inhibitor was 3 x 10- M. 
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Table .2. 
Effect of Continuously Infused Ep453 On Experimental 
Metastasis 
Solution 
Infused a 
Control (PG) 
Ep453 (0.08 M in 
propylene glycol 
(PG)) 
Number of Lung Metastases 
per Animal 
13,22,27,33,44,49,>300,>300 
17,25,25,43,66,79,90,105 
Mean 
(± S.E.) 
asolution in 0 infused into animal from Alzet mini-osmotic pumps 
surgically implanted into mice. Rates of infusion were 1 uL/hr 
over 5 to 7 days. Steady-state concentration of Ep453 in mouse 
plasma during infusion of inhibitor was 3 x 10-7 M. 
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cathepsin B on metastasis. In this experiment the plasma level of 
Ep475 was 3 x 10-7 M. As shown in Table 6, this concentration of 
an irreversible inhibitor of cathepsin B also had no significant 
effect on the formation of metastatic lung colonies. 
EFFECT .Qr. THROMBIN INHIBITORS .QN. METASTASIS 
In experimental models for metastasis, prior evidence has 
indicated that the attachment of circulating tumor cells is an 
important step leading to metastasis. Treatment with anti-
coagulation drugs or drugs which inhibit platelet aggregation have 
been shown in some instances to reduce metastasis. However, many 
of these compounds have other effects in addition to their anti-
coagulation properties. Since thrombin is believed to play an 
important role in the attachment of circulating tumor cells and 
tumor cell/platelet emboli, the specific thrombin inhibitors t-
boc-D-Phe-Pro-Argininal and D-Phe-Pro-Argininal were injected into 
mice by the same protocols that were used for inhibitors of 
cathepsin B. Injection of 50 mg/kg of t-boc-D-Phe-Pro-Argininal 
was fatal to 5 of the mice in experiment 1, Table 7. This 
experiment was continued using injections of 12.5 mg/kg. Because 
of this toxicity, slightly lower doses of these compounds (37.5 or 
25 mg/kg) were used. These doses were tolerated well by the 
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Table 1-
Effect of i.p. Injected R-D-Phe-Pro-Argininals on Experimental 
Metastasis 
Experimental 
Treatmenta 
1. 
Control 
Boc-D-Phe-Pro-Argal 
(1x50, then 12.5) 
2. 
Control 
Boc-D-Phe-Pro-Argal 
(37.5) 
3. 
( 20 ,000 cells) 
Control 
Boc-D-Phe-Pro-Argal 
(25) 
4. 
Control 
D-Phe-Pro-Argal 
(37.5) 
Number of Lung Metastases 
per Animal 
13,17,21,21,37,47,51 
9,29,47 
1,23,33,41,54,59,121 
12,25,26,31,36,48,62,79,118,180 
o,o,o, 1, 1, 1,9, 10, 10 
0 , 1 , 1 , 1 , 1 , 2 , 2 , 2 , 2 , 3 , 6 , 14 , 1 7 , 36 
5, 6 , 6, 14, 15, 20, 21 , 36 , 36, 41 , 60, 
7,18,23,24,29,38,46,62,62,64, 
Mean 
(± S.E.) 
3o±6 
28 
3. 6±1. 5 
6,3±2.1 
24±s.3 
37.±6,5 
aNumbers in () indicate mg/kg injected i.p. every 12 hours for 
5.5 days. Control animals received injections of the drug 
vehicle. Argal is an abbreviation for argininal. 
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animals. In experiment 3 (Table 7), several of the mice (3) died 
before the end of the experiment, and several were lethargic with 
difficulty in hind leg motion. Several of these animals were 
autopsied and appeared normal, except ror the tumors. In 4 
animals on which complete autopsies were performed, metastases 
were found outside the pleural cavity in three animals; 2 of these 
were in the kidneys and one each in the lymph node and at a 
subcutaneous site. It is believed that the effects seen in these 
animals were due to tumor burden, possibly due to the length of 
this experiment (21 days). Similar rear body effects on motion 
were observed in animals of the control groups and treated groups. 
It was also noticed that in experiment 2 (Table 7) in which the 
higher dose of the t-boc-D-Phe-Pro-Argininal compound (37.5 mg/kg) 
was used, the animals in the treated group appeared to have 
bruises on their abdominal region. This differed rrom the control 
and leupeptin ·animals where the abdominal region toughened with 
scar tissue from the repeated injections. Some of the animals 
receiving this dose (37.5 mg/kg) of the t-boc-D-Phe-Pro-Argininal 
also showed susceptibility to bleeding when handled by the tail. 
In Table 7 it can be clearly seen that the specific 
inhibitors of thrombin had no significant effect on metastasis. 
This was the result when t-boc-D-Phe-Pro-Argininal or D-Phe-Pro-
Argininal was used, and did not vary when the number of tumor 
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cells injected was decreased (experiment 3, Table 7). In fact, in 
3 of the experiments (experiments 2, 3, and 4, Table 7), these 
compounds showed a slight promotion effect, causing the number of 
lung colonies to increase by an average of 40%. 
Again, in order to make sure that the concentrations of drug 
.in.Y.1.YQ. were sufficient to inhibit thrombin, the blood levels were 
assayed following i.p. injection. A 37.5 mg/kg injection of t-
boc-D-Phe-Pro-Argininal resulted in plasma levels of 1 x 10-6M 
after 30 minutes and 4 x 10-7M after 1 hr. After 1 hr, no 
inhibitor could be detected. Therefore, these experiments were 
repeated using the osmotic pump procedure described previously. 
Loading the pumps with a 0.25 M solution of D-Phe-Pro-Argininal 
resulted in a steady state level of inhibitor at a concentration 
of 4 x 10-7M. This is higher than the Ki of this compound for 
thrombin, but lower than the Ki values for the other implicated 
proteases (Table 1), so that in these experiments thrombin should 
be effectively and specifically inhibited. This treatment 
increased the number of lung colonies dramatically as shown in 
Table 8. In two separate experiments the treated group averaged 
over 300 individual lung colonies, while the control groups 
averaged close to ten. 
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Table .a 
Effect of Continuously Infused D-Phe-Pro-Argininal On Experimental 
Metastasis 
Solution Number of Lung Metastases Mean 
Infused a per Animal (± S.E.) 
1. 
Control (40%DMSO) 4,4,4,6,8,9,12,13 7.5±1.3 
D-Phe-Pro-Argal 
(0.25 M in 40% 229,>300,>300,>300,>300,>300 
>300b DMSO-PBS) >300,>300,>300,>300 
2. 
Control (40%DMSO) 7,8,11,12,13,18 12±1. 4 
D-Phe-Pro-Argal 
>300b (0.25 M in 40% 104,>300,>300,>300,>300,>300 
DMSO-PBS) 
asolution in () infused into animal from Alzet mini-osmotic pumps 
surgically implanted into mice. Rates of infusion were 1 uL/hr 
over 5 to 7 days. Steady-state concentration of D-Phe-Pro-
Argininal in mouse plasma during infusion of inhibitor was 4 x 
10-7 M. bvalue is significantly different from control at P < 
0.001. Argal is an abbreviation for argininal. 
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EFFECT OF PLASMINOGEN ACTIVATOR INHIBITORS ON METASTASIS 
Because of the higher Ki values of the R-Glu-Gly-Argininal 
inhibitors against their targeted protease, urokinase (Table 1), 
higher .in~ concentrations of these compounds were needed to 
examine their effect on metastasis. The blood level of these 
compounds was measured following i.p. injections as described in 
the methods section. It was found that after a 30 mg injection, 
the compound was only detected (as measured by inhibition of 
urokinase, lower limit 1 x 10-5 M) for 1-2 hr. Due to these 
features of the R-Glu-Gly-Argininal compounds, (high Ki values, 
rapid turnover i.n.Y..iYQ), it was impossible to use osmotic pumps to 
deliver these compounds. Accordingly, maximum doses (30mg) 
tolerated by the animals were injected i.p. every 2-4 hours for 
the first 1-1.5 days. The results are shown in Table 9. The free 
(tfa) Glu-Gly-Argininal compound appeared to be more toxic than 
the t-boc-Glu-Gly-Argininal. At these doses, both compounds 
appeared to make the mice lethargic and somewhat stiff in motion 
(in the (tfa) Glu-Gly-Argininal experiment, 2 of the smallest mice 
died; these mice received a higher dose per kg and were also 
clearly not as vigorous as the others before the experiments). 
However all the mice recovered rapidly (within 24 hours) after the 
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Table .9. 
Effect of i.p. Injected R-Glu-Gly-Argininals on Experimental 
Metastasis 
Experimental 
Treatmenta 
1. 
Control 
Boc-Glu-Gly-Argal 
(30 mg i.p. per animal; 
8 times over 36 hr) 
2. 
Control 
H-Glu-Gly-Argal 
(30 mg i.p. per animal; 
6 times over 25 hr) 
Number of Lung Metastases 
per Animal 
122,165,177,180,220,230,260, 
>300,>300,>300 
62,68,154,160,178,>300,>300 
87,89,122,122,128,149,189 
214,279,>300,>300,>300 
Mean 
(±s.E.) 
aNumbers in ( ) indicate mg/kg injected i.p. every 12 hours for 
5.5 days. Control animals received injections of the drug 
vehicle. Argal is an abbreviation for argininal. bSignificantly 
different from control at P < 0.001. 
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injections had ceased. These inhibitors also failed to reduce 
metastasis, even at the high doses used in this experiment. The 
promotion of lung colonization seen in experiment 2, although 
significant, must be considered with caution due to the possible 
toxic side effects of the high doses of drug used in this study. 
RESULTS OF PLASMINOGEN ACTIVATOR STUDIES 
Because of the strong evidence for a role of PA in 
metastasis, attempts were made to study the PAs secreted by the 
B16 melanoma in culture. The susceptibility of the secreted 
enzyme to inhibition by the tripeptide aldehyde inhibitors was 
estimated using concentrated media prepared by different 
procedures. Those reported (Table 10) were performed using an 
Amicon concentrate (500 ml concentrated to 2.5 ml) and were 
determined under the conditions described in methods. Inhibition 
constants were determined by measuring the rate of hydrolysis of 
S-2444 in the presence and absence of inhibitor. This substrate 
(S-2444) has been shown to be specific for UK with a Km of 6 x 
10-5 M (Kabi). Preliminary data (Table 11, Figure 2) indicated 
that although plasminogen is the only known protein substrate for 
both UK and tPA, they have different specificities for small 
substrates. The Km of S-2444 determined against human rt-PA was 
approximately 1.5 x 10-3 M. This indicates that S-2444 is a 25-
fold better substrate for UK than for tPA. Thus, these Ki's give 
an estimate of the susceptibility of the UK-like enzyme present in 
serum-free conditioned medium (SFCM) to inhibition by the 
aldehydes used in this study. Several of these inhibitors gave 
91 
92 
TABLE .1.Q. 
Inhibition of urokinase-like activity in 
concentrated SFCM by tripeptide aldehydes 
-----------------------------------------
tripeptide aldehyde K. a M 1 
- - -- - - - - --------------------------
(tfa)Glu-Gly-Argininal 
t-boc-Glu-Gly-Argininal 
DNS-Glu-Gly-Argininal 
D-Phe-Pro-Argininal 
t-boc-D-Phe-Pro-Argininal 
leupeptin 
3.0 x 10-4 
(1.59 x 10-4 , 2.64 x 10-4 , 4.76 x 
10-4> 
4.o x 1 o-4 
(4.5 x 10-4 , 3.4 x 10-4) 
2.1 x 10-4 
(9.5 x 10-5 , 3.2 x 10-4) 
9.8 x 10-5 
(1.43 x 10-4 , 5.37 x 10-5) 
2.5 x 1 o-6 
(9.3 x 10-7, 4 x 10-6) 
1.6 x 1 o-4 
c 3 x 1 o- 4 , 2.59 x 1 o-5) 
------- -------------
a Inhibition constants were determined in 1.1 mls. 0.05 M tris pH 
8.8 containing 30 KIU of aprotinin and 100 ul concentrated S~CM. 
Substrate (S-2444) was at a final concentration of 1.1 x 10- M. 
The Ki is the average of the individual values in parentheses. 
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Table ll 
Determination of ~ of S-2444 for rtPA 
SUBSTRATE INITIAL RATE {v)a S/v 
M x 103 M/min. x 107 min x 10-4 
3.6 3.3 1 • 1 
1. 82 2.7 0.67 
0.91 1. 7 0.54 
0.45 1. 1 0.41 
--a-Rea~ti~;s were pe;for;;d i;-~-ri~~l volume of 1.225 mls. of 
0.05 M tris buffer pH 8.8, using a stock substrate solution of 1 x 
10-2 M and 25 ul of a 0.1 mg/ml solution of rtPA. See Figure 3 for 
plot of data. 
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Figure 2. Determination of Km of S-2444 for rtPA. 
A plot of S/v vs. S gives a straight line with a 
correlation coefficient of 0.99 by linear regression. 
From the Hanes plot, S/v = Km/V + S/V, the slope = 1/V 
and the intercept = Km/V, giving a Km of 
1.5 x 10-3 M. 
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similar Ki's against this preparation, but in this crude 
preparation it is probable that more than one enzyme was taking 
part in the reaction. Electrophoresis gels of the concentrated 
media showed many protein bands, and when overlayed on fibrin agar 
indicator gels, several bands of lysis were observed. This is 
clearly illustrated in Figure 3. No lysis was observed in fibrin 
plates in which the plasminogen had been denatured. These bands 
varied in appearance but always consisted of a combination of the 
three shown in Figure 3. These bands could be interpreted in 
several ways (partially degraded forms, different enzymes, enzyme 
inhibitor complexes), but it is now clear that they represent 
synthesis of both types of PA (tissue and urokinase) by the B16 
cells. 
In order to obtain a better estimate of these Kis, several 
attempts were made at purifying the enzyme; these were hampered 
principally by the low amounts of activity present in the initial 
starting material. Serum free conditioned media contained 
approximately 4000 to 5000 mU/L of UK-like activity as measured 
by S-2444 hydrolysis. Attempts to grow cells in SFM for extended 
lengths of time or in media containing serum supplements proved 
unsatisfactory, and the small amounts of conditioned media 
obtained by traditional cell culture were inadequate for detailed 
study. After initial attempts using a peptide aldehyde column, 
97 
Figure 3. Photograph of electrophoresis gel 
stained in Coomassie Blue after overlaying on fibrin 
agar indicator gel. Sample was concentrated B16 
melanoma SFCM. 
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the use of a p-aminobenzamidine column was found to result in 
reproducible binding of the enzyme activity. After several 
modifications were attempted, the purification procedure outlined 
in the methods section was used to produce a preparation which 
produced a single major band of lysis following gel 
electrophoresis and zymography on a fibrin-agar plate (Figure 4). 
Mouse urine (25 ul) was electrophoresed in an adjacent lane, and 
produced two bands of lysis corresponding to the low (30,000) and 
high (48,000) molecular weight forms of urokinase. Samples were 
always electrophoresed in triplicate and the gels were sliced into 
three equal sections. One of the gel sections was stained in 
Coomassie Blue. The two remaining sections were prepared for 
zymography. One was overlayed on a fibrin-agar gel to detect PA 
activity and the other was overlayed on a fibrin-agar plate in 
which the plasminogen had been denatured to control for 
plasminogen independant lysis. No lysis was observed on the 
control plates. It is clear from the position of the lysis bands 
that the sample (50 ul) contained a qualitatively different 
plasminogen activator. From the position of mouse tissue type PA 
(see Figure 5), it was concluded that the majority of the PA 
activity in the partially purified sample was of the tissue type. 
This single-step chromatography procedure resulted in a yield of 
about 30% and about a 100-fold purification, although these 
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Figure 4. Photograph of fibrin agar underlay 
showing bands of lysis produced by overlaying with 
electrophoresis gel containing samples of partially 
purified B16 PA (lanes 1 and 2) and mouse urine (lane 
3). 
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numbers are based in S-2444 hydrolysis activity and the protein 
determinations were obtained in the presence of detergents and 
high concentrations of other materials. A second preparation 
purified from a different batch of SFCM, resulted in a single band 
of lysis when electrophoresed and overlayed on a fibrin-agar 
plate. This single partially purified activity is shown clearly 
in Figure 5, where samples of concentrated SFCM, partially 
purified PA from SFCM, mouse urine, and mouse lung homogenate were 
electrophoresed on the same gel. Mouse urine is known to contain 
only UK and mouse lung is known to show tPA and UK PA activity. 
Comparing these "standards" to the B16 samples, it is clear that 
both enzymes are present in the sample of concentrated medium 
while the partially purified preparation only shows a tPA band. 
The Coomassie Blue stained gel is shown for comparison in Figure 
6. That this preparation consisted solely of tPA was demonstrated 
by showing that the plasminogen activator activity was completely 
inhibited by anti-tPA antibody and completely resistant to anti-UK 
antibody. After incubation with the specific antibody preparation, 
samples were assayed for their ability to activate plasminogen and 
produce lysis on a fibrin-agar plate. The result is shown in 
Figure 7, which was photographed 5 days after the samples were 
applied. The complete inhibition of lysis by anti-tPA antibody 
clearly indicates that this sample contained only mouse tPA. 
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Figure 5. Fibrin agar underlay showing bands of 
lysis produced by electrophoresing mouse urine (lane 
1), concentrated B16 SFCM (lane 2), partially purified 
PA from B16 SFCM (lane 3), and homogenized mouse lung 
tissue (lane 4). This pattern of lysis did not change 
after five days. 
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Figure 6. Stained electrophoresis gel 
corresponding to that overlayed in figure 15. Samples 
are urine (lane 1), concentrated SFCM (lane 2), 
partially purified PA from B16 SFCM (lane 3), 
homogenized mouse lung tissue (lane 4), and molecular 
weight standards (lane 5). Molecular weights of 
standards are: a= 92,000, b = 66,000, c = 45,000, d = 
31,000, e = 25,000, and f = 17,000. 
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Figure 7. Antibody inhibition of lysis on fibrin 
agar indicator gel by partially purified PA from B16 
SFCM. Wells 3 and 6 are controls, wells 2 and 5 
contained anti-tPA antibody, and wells 1 and 4 
contained anti-UK antibody. 
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Direct activation of plasminogen by a partially purified 
preparation of mouse tPA using the coupled plasminogen-S-2251 
assay is shown in Figure 8. The effect on this activation by 
pretreatment with the irreversible inhibitors DFP and pCMB is also 
shown. DFP completely inhibited the activity of the mouse tPA 
sample, while pCMB had no effect. These inhibitors gave the same 
result when the hydrolysis of the synthetic substrate S-2444 
(Figure 9) was measured. These results confirm the serine-type 
nature of the isolated PA activity. Inhibition constants for the 
tripeptide aldehydes determined against this partially purified 
preparation are listed in Table 12. 
Inhibition constants for a purified sample of recombinant 
human tPA (rtPA) were also obtained under the same conditions. 
These are shown in Table 13. An example of the inhibition 
experiments is shown in Figure 10. It can be noted that the 
specificity of the inhibitors against this purified preparation of 
human rtPA, consisting of a mixture of one and two chain forms, 
follows the same pattern as that for the partially purified PA 
preparation from the B16 melanoma. These results indicate that 
tPA (Table 13) has a very different specificity towards small 
peptides than urokinase (Table 1), even though their natural 
substrate is identical (plasminogen). 
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Figure 8. Spectrophotometer tracing showing the 
direct activation of plasminogen by a partially 
purified preparation of B16 melanoma PA and the effect 
of DFP and pCME. The control reaction is shown in A), 
inhibitjon by DFP is shown in B), and lack of an effect 
of pCMB is shown in C). Arrow indicates point of 
addition of UK to verify DFP treatment was not 
inhibiting plasrni~ 
~A------------------~1 
r-~8 --------__,..01 
-----+----~~~--+====:10 
r::c:-------------------01 
4~0-----3~0 ____ __,2~0=----.... 10------10° 
minutes 
, 11 
112 
Figure 9. Spectrophotometer tracing showing the 
hydrolysis of S-2444 by a partially purified 
preparation of B16 melanoma PA before and after 
incubation with the irreversible pr·otease inhibitors 
DFP and pCMB. A) is the control reaction, B) is after 
treatment with DFP, and C) is after treatment with 
pCMB. 
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TABLE .1Z. 
Inhibition of a partially purified preparation 
of B16 melanoma tPA by tripeptide aldehydes. 
--------
tripeptide aldehyde K a i 
----------
(tfa)Glu-Gly-Argininal 1.1 x 10-2 
t-boc-Glu-Gly-Argininal 7.5 x 10-3 
DNS-Glu-Gly-Argininal 1.6 x 10-3 
D-Phe-Pro-Argininal 8.3 x 10-5 
t-boc-D-Phe-Pro-Argininal 5.5 x 10-6 
leupeptin 3.3 x 10-4 
aKi s were esti;;ted -i~-~ -ri~~i-vo~~;;-~r-1~1- ml~-0.05 M Tris-0.025 
M EDTA pH 8.8 containing 1.1 x 10- M substrate (S-2444). 100 ul 
of the enzyme solution was incubated with the inhibitor to be 
tested and 30 K!U aprotinin in buffer for 15 minutes before the 
reaction was started by addition of substrate. 
115 
TABLE 11 
Inhibition of human rtPA by tripeptide aldehydes 
tripeptide aldehyde 
(tfa)Glu-Gly-Argininal 
3.97 x 10-4 b (2) 
1.19 x 10-3 b (2) 
t-boc-Glu-Gly-Argininal 
5.1 x 10-4 b (2) 
2.05 x 10-4 b (2) 
DNS-Glu-Gly-Argininal 
6.36 x 10-56 b (3) 
6.36 x 10- b (3) 
D-Phe-Pro-Argininal 
8.97 x 10-5 b (2) 
3.59 x 10-5 b (3) 
t-boc-D-Phe-Pro-Argininal 
1.24 x 10-6 b (3) 
1.24 x 10-7 b (3) 
leupeptin 
4.6 x 10-5 b (3) 
1.84 x 10-5 b (3) 
K.a M 
1 
.3.J x .iQ3 
3.34 .± 0.64 x 10-3 c 
3.33 .± 0.10 x 10-3 c 
1.85 .± 0.11 x 10-3 c 
1.66 .± 0.35 x 10-3 c 
Ll x .w.=5-
3.19 .± 0.3 x 10-5 c 
2.39 .± 0.05 x 10-5 c 
1.78 ± 0.07 x 10-5 c 
1.60 ± 0.09 x 10-5 c 
Ll.. x 1Q:=1. 
1.88 + 0.09 x 10-7 c 
2.35 :±: 0.2 x 10-7 c 
-9...R ~ 1o=2-
8. 92 ± 0.32 x 10-~ c 
9.44 ± 0.21 x 10- c 
a is the average of two Ki values obtained using the two 
inhibitor concentrations designated as b. The individual Kj 
values designated as c, are shown.± standard deviation. (NJ i~ 
the number of experimental runs. 
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Figure 10. Spectrophotometer tracing showing the 
inhibition of rtPA activity by D-Phe-Pro-Argininal. A) 
is the control1 B), C), and D) were in the presence of 
3.6 x 1 o-5 M D-Phe-Pro-Argininal. 
0.10 - 1~~~----·-----------~-------------------'--------· 
,-· 
·- -_,, _ .... 
·-··· ·-'"·-....: 
.... ,, --
..... · 
_ _.,.,-· 
- .:::. .... .::· . 
•• ·-J'" -
_,_. ,.. . 
,_,. ... 
, .. ..,. 
.~ ..... . -
a .,. .. -· . 
. ,..· 
_.,, 
,_ . 
(\. 00 . --------------·-.-------------· 
0.00 M I II UT [ 5 
........ -
__ ... -·. 
30.00 
DISCUSSION 
Metastasis can be envisioned as a series of individual steps, 
although it is not necessary to assume that the tumor cells which 
metastasize participate in each of these. To metastasize, the 
cells of a growing tumor must invade through normal tissue. This 
would often include degradation of a fibrin capsule found around 
many primary tumors which is apparently formed outside the 
circulatory system. When the tumor cell reaches a blood vessel, 
or induces the formation of its own vascular system, it must 
degrade the basement membrane and intravasate into the 
circulation. The tumor cells in circulation must then attach to 
the endothelium or subendothelial matrix, again degrade the 
basement membrane, and extravasate into the normal tissue. Here 
the tumor cell(s) will divide and grow into a secondary tumor 
mass. It should be clear that the model used here only tests the 
hypothesized roles for proteases in the steps following the 
release of tumor cells into the circulation. Thus the roles of 
proteases in increasing the survival of tumor cells in 
circulation, the attachment of these cells, and the invasion of 
these cells into normal tissue from the bloodstream will be 
considered here. 
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The experiments reported here utilized the B16-F10 melanoma 
cell line, which was selected for its high potential to form lung 
colonies after i.v. injection. The B16 melanoma system, 
originally described by Fidler (1973), was chosen for these 
experiments for a number of reasons. Principle among these was the 
fact that the B16 melanoma developed spontaneously in the C57Bl6 
mice which are used in the experimental model. By using a natural 
tumor line in a syngeneic host, no assumptions about the role or 
the immune system need to be made, and the model is perhaps more 
relevant to the natural disease condition. Also, this cell line 
has been used in many studies and some of the correlations/ 
contradictions or increased protease and increased metastasis were 
performed on sublines of the original B16. This tumor also 
metastasizes spontaneously so the current study could easily be 
expanded to include the initial steps in metastasis. In addition, 
the use of mice instead of rats or guinea pigs allowed the total 
amount or the difficult to synthesize aldehydes to be kept 
reasonable. 
However, the model must be considered in terms of the work 
proposed. The aim of this research was to test the hypothesis that 
certain proteases participate in the processes or attachment 
(thrombin) and invasion (cathepsin B, plasminogen activator) of 
circulating tumor cells. It is clear that following i.v. injection 
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of tumor cells they must first arrest in the lungs and then 
extravasate into the lung parenchyma in order to develop into 
metastases. Therefore, the model does include the relevant steps 
of the metastatic process under study, and agents can be tested 
for their effects on this process. Another aspect of the model 
which must be considered is the ability to determine whether or 
not a specific treatment is producing an effect. In this work, a 
change in the number of metastatic colonies would be considered 
evidence of an effect on the metastatic process. Therefore it is 
important that the method for determining the number of lung 
colonies be accurate and reproducible. As stated by Fidler (1978), 
and discussed in the references therein, most lung tumors in mice 
appear on the surface and can be counted with a dissecting 
microscope. In two of these studies (Wexler, 1966; Wood 
~al, 1953), detailed microscopic examination of lung sections 
were compared to observations of surface colonies and found to 
give similar results. Thus prior evidence indicates that 
the enumeration of surface lung colonies would give an accurate 
indication of the total number of metastases, and any significant 
changes in the average number of metastases would be detected by 
this procedure (for example, see Figure 11). However, the 
treatments used in these experiments may result in an altered 
distribution of metastases, either within the lung or to other 
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Figure 11. Photograph illustrating lung lobes 
dissected into Jobes for counting of metastases. The 
upper lung (row a) contains > 300 individual metastatic 
colonies, while the lower lung (row b) only contained 
7. Animals were selected from those shown in table 5. 
a 
b 
_. 
I\) 
I\) 
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organs. The absence of extrapulmonary metastases was routinely 
verified by gross autopsies. However, in order to address the 
possibility of an altered distribution of metastases within the 
lung, two alternate possibilities have been considered. The first 
method, which has been~ed to study the initial arrest of tumor 
cells in organs (Fidler 1978), involves radiolabeling of the tumor 
cell innoculation with 11 25 2-iodo-deoxy-uridine. This procedure 
may have resulted in a more accurate determination of the number 
of injected tumor cells remaining in the lungs, and should be 
considered for future experiments. Another possibility when 
working with melanoma cells would be to use melanin as a measure 
of metastasis. This procedure has not been reported in the 
literature, and so would require preliminary evidence to verify 
its' usefulness. Also, the presence of amelanotic nodules in some 
experiments (as observed in this work) may result in difficulties 
in interpretation or in comparisons between experiments. Melanin 
is also a difficult compound to extract from tissue, requiring 
repeated refluxing in 6 N HCL (Jimbow ~.al.., 1984). 
The number of metastases varied between control groups in the 
experiments reported here. This probably was a result of using 
animals from different vendors, using cells which had been 
maintained in culture for different lengths of time, and 
inadvertant differences in the exact stage of growth and treatment 
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of the tumor cells when injected. Because the control for each 
experiment was always performed identically to the experimental 
group, this variation in average number of lung colonies should 
not affect the conclusions of this work. In addition, as stated 
above, the agents used are being tested for their ability to 
inhibit the attachment and invasion of the injected tumor cells. 
Since every tumor cell which develops into a metastases must 
complete these steps, it is the relative number of successful 
metastases between control and experimental animals which is 
important to consider, not the total number. 
In this work, tripeptide aldehydes were used to inhibit the 
proteolytic enzymes cathepsin B, PA, and thrombin in an in...Y.i:l.Q. 
model for metastasis. These compounds have been shown to be potent 
and specific inhibitors of these enzymes .in yitro. Treatment of 
animals with these inhibitors in a model for experimental 
metastasis would be expected to give clear evidence as to the 
importance of the inhibited enzymes in metastasis. For example, if 
leupeptin is the only compound to inhibit metastasis, it would be 
a strong indication that cathepsin B is involved. Alteratively, if 
D-Phe-Pro-Argininal is the only compound to inhibit metastasis, it 
would support the hypothesis that thrombin is important to the 
lodgement of i.v. injected tumor cells and thus is a crucial 
participant in the process of metastasis. If both D-Phe-Pro-
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Argininal and leupeptin produce a significant reduction in 
metastasis, it would indicate that cathepsin B and thrombin are 
important to the process of lung colonization. Or if these 
inhibitors reduced metastasis when used at higher concentrations, 
plasmin might be suggested to play a role in metastasis. By using 
a group of similar enzyme inhibitors of known specificity, it will 
be possible to clearly evaluate the effects of inhibiting specific 
enzymes on the metastatic process. This contrasts some of the 
earlier studies which used general protease inhibitors or 
inhibitors of unknown specificity. 
As noted above, cathepsin B has been implicated as an enzyme 
capable of much extracellular tissue destruction, including the 
degradation of type IV collagen. The production of high levels of 
cathepsin B has been shown to correlate with high levels of 
metastasis, and previously was believed to play a role in the 
coagulation and platelet aggregation of circulating tumor cells. 
If a cathepsin-B like protease is crucial to the metastatic 
process, then inhibition of its activities should lead to a 
reduction of metastasis. In the experiments reported here, this 
is clearly not the case. Using the strong cathepsin B inhibitor 
leupeptin, and following a protocol which was reported in the 
literature to result in significant reduction of metastasis, it 
was repeatedly demonstrated that in the B16 melanoma system used, 
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leupeptin produced no significant reduction (Table 2). Because 
the concentration of leupeptin following i.p. injection was found 
to be changing rapidly with time, these experiments were repeated 
using mini-osmotic pumps to maintain the concentration of 
leupeptin at a steady state level above the Ki of cathepsin B but 
below the Ki of other proteases for which there is a significant 
amount of evidence to support a role in metastasis. In these 
experiments therefore, the effect of leupeptin should be to 
selectively and efficiently inhibit cathepsin B. In previous work 
using leupeptin, the .1.n.~ concentration was not determined. 
From the turnover data reported here, it is clear that following 
i.p. injection of leupeptin, many proteolytic enzymes would be 
inhibited. Thus these prior experiments (Saito ~.al.., 1980) do 
not conclusively indicate the involvement of a particular 
protease. Again, in my experiments there was no reduction in lung 
colonies in the treated group versus the untreated (Table 5). 
Finally, both the injection and osmotic pump studies were repeated 
with a second potent inhibitor of cathepsin B, Ep453. This 
irreversible inhibitor, at the concentration used (3 x 10-7 M), 
would inhibit any soluble cathepsin B in the circulation. These 
experiments also failed to show any significant reduction of 
metastasis (Table 6). Taken together these results give strong 
evidence against an essential role for cathepsin B in the process 
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of lung colonization by B16 melanoma cells. These results are in 
agreement with previous experiments using leupeptin and pepstatin 
which also failed to show a reduction in metastasis, although 
these did not report the .i.n..Yi.Y.Q. concentration of inhibitor 
(Giraldi tl.al.., 1977c; Harvey tl.al.., 1977). 
There are at least two explanations for these results which 
would still be consistent with a role of cathepsin B in metastatic 
processes. First, the cathepsin B may not be completely inhibited 
by the circulating drugs. This may be possible if the circulating 
tumor cells attach to the substrate to be degraded first and then 
use a membrane bound form of cathepsin B to degrade it. For 
example, the cells may attach to the endothelium of small 
capillaries in the lungs and then utilize a membrane bound form of 
cathepsin B to degrade the basement membrane. Liotta and others 
(Terranova tl.al., 1984) have shown the importance of tumor cell 
attachment to the process of metastasis. It has also been shown 
{Quigley tl~, 1986) that when transformed cells are grown in 
contact with a normal subendothelial matrix, their degradation of 
this matrix cannot be completely inhibited by small protease 
inhibitors. In addition, under certain experimental conditions, 
enzymes are not susceptible to inhibition by protease inhibitors 
(Campbell tl .al.., 1982; Steven tl .al.., 1982). This could also 
apply to an extracellular enzyme secreted locally at the point of 
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degradation. In these localized extracellular spaces, the 
cathepsin B may be extremely resistant to soluble inhibitors. 
This could be due to the close localization of substrate and 
enzyme, which has the effect of increasing the substrate 
concentration. Because peptide aldehydes act as competitive 
inhibitors, at a high enough substrate concentration, their effect 
can be negated. Leupeptin has been shown to be ineffective at 
inhibiting B16 melanoma invasion in the amnion model at 
concentrations 100-fold higher than the Ki for UK, but antibodies 
against UK are effective inhibitors in this system (Rifkin, 1986). 
However, leupeptin has been shown to be effective at inhibiting 
intracellular degradation of proteins, and especially intra-
lysosomal proteins (Salminen~ .al,., 1984). The substrate 
concentrations in the lysosome would be expected to be quite high, 
and therefore it is unclear as to how an extracellular enzyme 
would not be inhibited at the levels of leupeptin (3 x 10-6 M) 
used in this experiment (Table 5). In addition, leupeptin has 
been shown to be effective at reducing protein degradation in 
models for muscular dystrophy (Sher ~.al_., 1981) at much lower 
doses than those used here. The use of two inhibitors with 
different mechanisms of action and properties also argues against 
the suggestion that cathepsin B is not inhibited in these 
experiments. A second possibility is that other enzymes, such as 
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PA, can degrade the same substrates as cathepsin B. For example, 
even if cathepsin B is inhibited 99%, tumor cell secreted UK may 
still be able to activate collagenase and degrade the basement 
membrane so that the overall process of metastasis is not 
inhibited. In this case increased cathepsin B might be involved 
in metastasis but may not be essential, or may not be involved in 
the rate limiting step. Another alternative is that increased 
release of cathepsin B-like enzymes may just be a phenotypic 
aberration of tumor cells. In addition, these experiments do not 
rule out a role of cathepsin B in the growth, invasion, or 
metastasis of the primary tumor. It is interesting to note that 
in the experiments which utilized injections, we did in one 
example note a statistical decrease in lung colonization, and 
consistently observed a reduction in the average number of lung 
colonies. It can be postulated that the high initial 
concentrations of leupeptin are inhibiting other proteases which 
are essential to the metastatic process. However, because the 
concentration of leupeptin drops rapidly, the enzyme is not 
inhibited long enough to significantly reduce metastasis. This 
might provide a partial explanation for the disagreement between 
the data reported here and that of Saito ~,al.. (1980). Saito ~ 
.al_. (1980) (using a different tumor line) report that leupeptin 
administered i.p. resulted in a decreased number of pulmonary 
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emboli following i.v. injection of tumor cells, and attributes 
this to the inhibition of thrombokinase. At the high initial 
concentration of leupeptin, factor Xa would be inhibited, as well 
as other enzymes. The effect of leupeptin on metastasis at 
concentrations higher than those used here should be investigated 
further. In other experiments, leupeptin has had mixed effects, 
but the concentrations .in.Yi.YQ. were not previously reported so that 
any conclusions from these experiments must be considered 
speculative. 
Treatment of experimental animals with the specific thrombin 
inhibitors R-D-Phe-Pro-Argininal by the i.p. protocol resulted in 
no significant change in the number of metastases, whereas 
administration of these compounds by the continuous infusion 
method resulted in a dramatic and significant increase in 
metastases. Again referring to the data of Saito~ .al, (1980), 
inhibition of thrombin activity would also be presumed to block 
the action of factor Xa on increased fibrin formation. The 
observation of an increased number of pulmonary nodules after 
treatment with a thrombin inhibitor contradicts a large body of 
evidence which supports the idea that fibrin formation and 
platelet aggregation are important steps in the process of 
successful blood borne metastasis. However, as discussed above 
most of the previous studies used coagulation inhibitors which had 
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many other effects in addition to inhibition of thrombin activity. 
Also, tumor cells have been shown to attach to endothelial cells, 
subendothelial matrices, and aggregate platelets (Tohgo ~ .ai_., 
1985) without the formation of fibrin. Fibrin formation therefore 
may be a consequence of other properties of metastasizing tumor 
cells, again without being essential to the process. It has been 
proposed that fibrin around a circulating tumor cell may be part 
of the host response in an attempt to keep the tumor cell from 
extravasating. Fibrin could then be proposed to play a similar 
role of preventing invasion of the circulating tumor cell and of 
the primary tumor. It is also possible that thrombin has other 
suppressive roles in metastasis so that inhibition of this enzyme 
leads to a promotion of experimental metastasis. Thrombin can not 
only catalyze the formation of fibrin and stimulate the secretion 
of inhibitors of fibrinolysis, but when bound to thrombomodulin 
(an endothelial cell surface protein found throughout the 
circulation (Ishii~ .al,.., 1986)) can also cause the activation of 
the fibrinolytic pathway. However, thrombin bound to 
thrombomodulin is rapidly internalized and degraded, and an 
inhibitor of activated protein C has also been described (Esmon, 
1983). In addition, Gelehrter and Sznycer-Laszuk (1986) showed 
that the direct effect of thrombin on endothelial cells was an 
increased secretion of PA inhibitor relative to PA, and hence a 
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decreased fibrinolytic activity. Also, some of the evidence which 
supports an enhancing role of thrombin and fibrin formation in 
metastasis is based on the direct observation of fibrin-containing 
tumor emboli in the target organs. Thus although the many diverse 
actions of thrombin can not be ignored, it's net effect in the 
process of blood-borne metastasis appears to be the formation of 
fibrin and a tumor cell embolus. Therefore, the net effect of a 
thrombin inhibitor should be to inhibit the formation of fibrin 
and tumor cell emboli. In the experiments reported here, the 
continuous inhibition of thrombin by infusion of D-Phe-Pro-
Argininal at a steady-state concentration of 4 x 10-7 M resulted 
in a significant increase of lung metastases following i.v. 
injection of tumor cells (Table 8). This would indicate that 
thrombin and presumably fibrin formation have an inhibitory effect 
on metastasis. 
It would be informative to examine the lungs of mice treated 
with D-Phe-Pro-Argininal at various times after the injection of 
the tumor cells, and compare the number of tumor emboli and the 
amount of associated fibrin with that found in untreated mice. 
Alternatively, the D-Phe-Pro-Argininal compounds may be having 
other effects. For example, the inhibition of thrombin may be 
resulting in a damaged endothelial cell layer, which would 
facilitate greater tumor cell attachment and invasion. In future 
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investigations, monitoring of the coagulation state of the animal 
may be useful to obtain a balance between inhibition of tumor cell 
attachment and other possible effects on the animal. Further 
research on the 1.n YiYQ effects of this compound is also 
necessary. 
The experiments using the R-Glu-Gly-Argininals to inhibit UK 
are not as conclusive as the experiments in which inhibitors of 
thrombin and cathepsin B were used. Because of the high Ki values, 
large amounts of these drugs had to be injected and this may have 
produced toxic effects. In addition because of the large amounts 
of these compounds needed and the limited capacity of the osmotic 
pumps, the osmotic diffusion pumps could not be used which 
resulted in a much shorter period of drug treatment in these 
experiments. However, if UK were required for tumor cell 
metastasis in this initial period (1.5-2 days after tumor cell 
injection), it would be expected that the concentrations of UK 
inhibitors used in this experimental procedure would have.resulted 
in a reduction in metastases. In the t-boc-Glu-Gly-Argininal 
experiment (Table 9), the number of lung colonies was similar in 
the treated and control groups, and in the (tfa)Glu-Gly-Argininal 
experiment there was a significant promotion of metastasis. The 
free compound appeared to produce more toxic effects than the t-
boc compound, and so this promotion of metastasis should be 
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considered with caution. 
The failure of UK inhibitors to reduce metastasis in these 
experiments can be explained by the same rationale used to explain 
the lack of an effect of cathepsin B inhibitors on metastasis (see 
above). Again, UK has been shown to exist in an active membrane 
bound form which may be resistant to inhibition after the cell is 
bound to the extracellular substrate (Vassall! ~.al,, 1985). In 
addition, only a small amount of active UK is necessary to quickly 
activate a significant amount of plasminogen, especially if the 
whole process occurred on the surface of a fibrin clot surrounding 
a tumor cell. Also, PAs may not be essential to tumor metastasis, 
but may play a role which can be fulfilled by another substituting 
protease, such as cathepsin B. These experiments also do not 
address the participation of PAs in the invasion and spread of the 
primary tumor. 
A further complication of these experiments comes from the 
demonstration that the B16 melanoma produces both the tPA and the 
UK PA. Although melanoma cells seem to be unique in their 
increased production of tPA, and UK is generally considered to be 
the enzyme involved in tissue degradation and the invasion and 
metastasis of tumors, this is partially an assumption and must be 
proven. In the experiments reported here, the tPA from the 
melanoma cells would not have been significantly inhibited even at 
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the high doses of inhibitor used. Thus it may be that the B16 
melanoma uses the tPA to facilitate extracellular degradation and 
metastasis, or it may use both, with either enzyme alone being 
sufficient to complete the metastatic cascade. The experiments 
reported here would still indicate that UK is not an essential 
participant in the lung colonization process. 
The production of PAs by the B16 melanoma has been correlated 
to the metastatic potential of this tumor cell line (Wang ~.al_., 
1980). There have also appeared contradictory reports which show a 
lack of correlation (Nicolson~ .sU..., 1976). Because of the 
strong evidence for a role of PAs in processes of invasion and 
metastasis, it was of interest to investigate the PAs produced by 
the B16 melanoma in culture. It was determined, by zymography and 
antibody studies, and confirmed by results from other laboratories 
(D. Belin, personal communication), that the B16 melanoma in 
culture produces both types of PAs, the tissue and urokinase type. 
In earlier experiments, i.e. Figure 3, recovered activity appeared 
to be largely UK type. In more recent experiments, (Figure 5), 
approximately equal amounts of both types of enzyme were present. 
This could represent a change in the phenotype of the cells due to 
the time which they have been maintained in culture or this could 
be due to changes in the procedure which resulted in preferential 
recovery. Other researchers have also reported varying amounts of 
synthesis of the two types of enzymes by B16 cells (D. Belin, 
personal communication). This situation could account for some of 
the contradictory evidence reported for the correlations of PA and 
metastatic potential in this cell line. If UK is the enzyme 
active in metastasis, measurements of total cellular or secreted 
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PA activity would not give a proper result since these 
would include the tPA activity (Camiolo and Greco, 1986). 
Measurements of secreted enzyme may also not correlate with 
metastasis, because in these and other experiments there is some 
indication that it is the membrane-bound proteases which actually 
participate in the local processes of tumor invasion. This 
situation is further complicated since both enzymes exhibit 
different activities in the presence and absence of fibrin, and 
exist in a variety of active forms which also differ in activity. 
Instead, antibody studies need to be performed which correlate the 
metastatic potential of a group of cells directly with a specific 
PA activity, for example, cell-associated UK activity. 
Because of the evidence suggesting that PAs are involved in 
the process of metastasis, it was of interest to study the PAs 
produced by the B16 melanoma. Inhibition constants were determined 
for a crude preparation of concentrated media using the UK 
specific substrate, S-2444 (Table 10). This substrate was shown 
by Km values to be approximately 10-fold better for UK over tPA, 
and in the concentrated media, other proteases were probably 
present which were not completely inhibited by the concentration 
of aprotinin used (30 KIU/ml). Therefore these Ki values only 
give an estimate of the inhibition of UK-like activity by the 
peptide aldehydes used. It has been shown by gene sequencing 
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however, that the UK type enzyme is very similar between species 
(Belin~ .aJ..., 1985). Therefore the inhibition constants obtained 
for human UK can be used as an indicator of the selectivity and 
effectivness of the tripeptide aldehydes against melanoma UK in 
the ..i.n YiY.Q. experiments. 
Attempts to purify the enzymes were hampered largely by the 
low amounts of PA present in conditioned media. In preliminary 
experiments, the use of a Gly-Gly-Argininal (Patel ~.al.., 1983) 
column was attempted with limited success. Because of the 
different specificity of tPA and UK (see below) it is probable 
that part of this result is due to the low affinity of tPA for 
this sequence. For this reason, a p-aminobenzamidine column was 
used. Because of large amounts of secreted melanin in original 
SFCM preparations, it was found useful to pass the medium through 
a DEAE-Sephadex column prior to the affinity resin. In this way 
melanin and possibly other contaminants were removed and the 
benzamidine column could be continuously reused. Further 
purification of the PAs was attempted using aprotinin and soybean 
trypsin inhibitor affinity resins, G-25 Sephadex, and HPLC 
columns. Again, the low amounts of activity made these studies 
difficult, and in several experiments the enzyme activity was 
unstable. 
The Ki values for the partially purified PA prep shown in 
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Table 12 show that the tPA has a markedly different specificity 
for small substrates than UK. This preparation was shown to 
consist only of tPA by the migration pattern on SDS-gel 
electrophoresis and the antibody study shown in Figure 7. It was 
shown to be able to activate plasminogen directly by the fibrin 
plate and the coupled plasminogen-S-2251 assay. The lack of 
hydrolysis of S-2251 or of significant inhibition by aprotinin is 
an indication of purity, at least of plasmin or other trypsin like 
proteases. The activity of this preparation was completely 
abolished by DFP and was not altered by pCMB, evidence for the 
serine type nature of the enzyme. The Ki values follow the same 
specificity pattern as those obtained for purified rtPA listed in 
Table 13. The Ki value for DNS-Glu-Gly-Argininal agrees with the 
Ki value of > 9 x10-6 M for DNS-Glu-Gly-Arginine-
chloromethylketone reported by Genetech (D. Higgins, personal 
communication to Dr. Schultz). It will be noticed that the 
absolute values differ by about an order of magnitude between the 
rtPA and the partially purified B16 melanoma tPA. This is 
possibly due to the impurity of the B16 preparation. It may also 
be due to differences in the amount of one chain, two chain or 
partially degraded enzyme present. From these data it can be 
concluded that the murine PAs are similar to the human and that 
the B16 melanoma is a relevant model for human melanoma in that 
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both lines produce tPA. It is also clear that the i.n ~ 
inhibitor studies did not involve inhibition of tPA and so the 
role of UK was tested independently. Further studies need to be 
done in order to develop different compounds to be used as 
specific inhibitors of tPA, so that the role of tPA and UK can be 
assessed independently and jointly. 
SUMMARY AND CONCLUSIONS 
Proteolytic enzymes are believed to have an essential role in 
the complex process of metastasis. Much prior evidence has 
accumulated which supports the theory that an increase in 
proteolytic enzymes results in an increased metastatic potential. 
However, these experiments often consist of indirect correlations, 
such as a comparison of the amount of protease secreted by tumor 
cells in culture and their metastatic potential J..n.~. In this 
work, direct inhibition of three of the proteinases believed to be 
involved (cathepsin B, urokinase, and thrombin) has been 
investigated as a means of clarifying the role of specific enzymes 
in this complex process, with the long-range goal of identifying 
sites of possible therapeutic intervention. Inhibitors of 
cathepsin B (leupeptin, Ep453), thrombin (R-D-Phe-Pro-Argininals), 
and urokinase (R-Glu-Gly-Argininals), were used to treat C57BL6 
mice which were injected i.v. with B16-F10 melanoma cells to model 
the later stages of metastasis. These inhibitors have been shown 
J..n yitro to be potent and selective at inhibiting the proteolytic 
enzymes under investigation. Inhibitors were introduced by i.p. 
injection or continuous infusion using Alzet mini-osmotic 
diffusion pumps. Injection of inhibitors resulted in rapidly 
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changing drug levels, while infusion of inhibitors resulted in a 
constant, steady-state plasma level of drug for at least 5 days. 
The plasma level was at a concentration specific for the targeted 
proteinase. This is a significant improvement over previous 
studies of this type, which utilized general proteinase inhibitors 
of undefined specificity and did not determine the inhibitors' .in 
.Yi.YQ. concentration. Under these conditions, inhibitors of 
cathepsin B, at concentrations orders of magnitude higher their 
Kis', sho-wed no effect on metastasis by any of the pr·otocols and 
dosages used. The conclusion from this work is that a cathepsin B-
like enzyme is not essential to the process of lung colonization 
even though much .in vitro work has implied that cathepsin B is 
involved in metastasis. Injection of inhibitors of urokinase also 
had no clear effect, suggesting that secreted UK may not be 
essential to the colonization process. However, continuous 
infusion of the specific thrombin inhibitor at levels higher than 
it's equi1ibrium Ki, resulted in a large significant increase in 
metastasis (300 vs. 10 lung colonies). This implies that the 
formation of ribrin by thrombin may have a retarding effect on the 
later stages of the metastatic process, in contradiction to much 
current literature which suggests thci.t fibrin formation by 
thrombin acts to increase the attachment of circulating tumor 
cells in the target organ. The experiments reported here did not 
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addresr: the role of pr·ot.eases in the initial stages of metastasis, 
and further studies of this type are necessary to clearly identify 
the roles of proteolytic enzymes in the complete metastatic 
process. 
Studies of conditioned medium from B16-F10 cells grown in 
culture revealed, by zymography and antibody tests, varying 
amounts of tissue type and urokinase type plasminogen activators. 
The tissue type plasminogen activator was isolated and compared 
to purified human recombinant tissue type plasminogen activator 
for sensitivity to inhibition by a series of tripeptide aldehydes. 
The two enzymes were found to exhibit similar specificity, with t-
boc-D-Phe-Pro-Argininal being the best inhibitor. This differs 
from the urokinase type enzyme, which was most sensitive to the 
sequence Glu-Gly-Argininal. These results indicate the need to 
develop specific inhibitors for UK and tPA in order to further 
examine their possible roles in metastasis .1n Yi.Y.Q,. 
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APPENDIX B 
Several variations of the basic procedure for collecting 
serum-free conditioned medium (SFCM) from the B16 melanoma were 
attempted. The first of these consisted of growing the cells in 
cycles of complete medium and serum-free medium (SFM). Thus cells 
were grown in complete medium until semi-confluent (as observed 
under the light microscope), washed in 5 ml of PBS twice, 
incubated in SFM for one day, after which the SFCM was collected and 
the cells were reincubated in complete medium. The cells 
maintained a healthy morphology under these conditions, but 
continued to increase in density when incubated in complete 
medium. When washed in PBS and recycled in SFM for a second day, 
large numbers of the cells detached from the tissue culture 
flask and a large quantity of cellular debris was evident in the 
medium. Therefore this procedure was not used, as the floating 
cells and debris was taken as an indication of cell lysis and 
death, which would release many proteolytic enzymes and other 
contaminants which would complicate the purification scheme. 
Flasks were also cycled in SFM for two days before being 
reincubated in complete medium, followed by another cycle of SFM 
with similar results. 
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A second possibility was to select for a population of cells 
which would be able to be maintained in SFM for extended lengths 
of time. This was attempted by culturing B16-F10 cells in complete 
medium until semi-confluent and then refeeding them only in SFM. 
These cultures approached confluency and then large numbers of the 
cells would release from the surface of the flask. These were 
removed with media changes and the cells remaining attached were 
refed in SFM. After several passages, the remaining cells (which 
were very scarce and no longer seemed to be replicating), were 
reincubated with medium containing calf serum (5% or 10%). The 
cells proliferated in the complete medium until a semi-confluent 
state was again reached, and then the selection procedure of 
growth in SFM only was repeated. The results were very similar to 
the first selection, with very few cells actually remaining 
attached (<10%). This procedure was abandoned for the following 
reasons: i) a truly stable population of cells capable of long-
term culture in SFM was not identified, ii) the cells which did 
survive in SFM for several cycles did not appear morphologically 
"healthy" (small, more spindly) when compared to B16-F10 grown in 
complete medium, iii) when the SFCM from these cells was examined 
by polyacrylamide gel electrophoresis and zymography, although the 
amount of protein was very low, the amount of PA activity detected 
was also low. 
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The use of serum supplements was explored as a third 
possibility for obtaining larger amounts of SFCM efficiently. 
Ultroser G (LKB, Bromma, Sweden) was used for these studies because 
many cell types have been successfully cultured using this as a 
serum supplement. Ultroser G contains necessary growth and 
adhesion factors, hormones, binding proteins, vitamins, and 
mineral trace elements. B16-F10 cells grown to semi-confluency 
were adapted to growth in Ultroser G by first replacing one-half 
of their medium with SFM containing 1% Ultroser G. This was 
completely replaced with 1% Ultroser G in SFM after 24 hr. Under 
these conditions, cells maintained a healthy morphology, however 
the cultures did not increase in number, even with daily 
refeedings. Increasing the Ultroser G content to 2% resulted in 
increased growth of the cultures. However, this procedure was also 
found to be unsuccessful because of the following considerations: 
i) When cultured in Ultroser G, the B16-F10 cells failed to 
produce notable amounts of melanin. This was a significant change 
from the cellular phenotype observed when cultured in complete 
medium. It was desireable to study the PA produced by the melanoma 
cells under conditions as close as possible to those used for 
preparing the cells for the .in vivo studies. Ultroser G was thus 
not suitable. 
ii) Electrophoresis and zymography of Ultroser G conditioned 
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medium revealed a significant amount of PA activity, but the 
activity was smeared by a large protein band and migrated slightly 
below the position of mouse UK. This difference was not explored 
further, but again indicated that the change in culture conditions 
was having an effect on the desired product, PA. 
iii) It was not possible to maintain cells in Ultroser G for 
truly extended lengths of time. Thus the procedure was not much 
more efficient than growing the B16-F10 cells in complete media. 
In addition, Ultroser G became unavailable for import shortly 
after these studies began. 
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APPENDIX C 
Nodules in mouse lungs which contained melanin were easily 
distinguishable from the normal tissue, and because of the 
presence of melanin, were identified as melanomas arising from the 
injected B16-F10 cells. However, the appearance of amelanotic 
nodules in some experiments required the use of another technique 
to verify that the nodules were in fact melanomas. As discussed by 
Mackay and Osborne ( pg.379, 1978), the presence of premelanosomes 
as visualized by electron microscopy is definitive evidence which 
allows the tissue to be positively identified as arising from a 
melanoma. With the kind and generous help of Dr. Bruce Persky, 
samples of both amelanotic and melanotic nodules were examined by 
transmission electron microscopy, by techniques previously 
described (Persky and Chmielewski, 1986; Persky~ .s.l_., 1986) and 
outlined below. 
Mice were sacrificed by cervical dislocation and the lungs 
were quickly removed, dissected free of other tissues, and rapidly 
rinsed in phosphate buffered saline to remove debris. Samples 
containing amelanotic and melanotic nodules were then carefully 
cut from the lungs in cubes (1 mm3 or smaller) and immediately 
immersed in modified Karnovsky fixative (1% paraformaldehyde, 
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1.25% glutaraldehyde pH 7.4) for 24 hr. The samples were then 
postfixed in 2% Os04 buffered in 0.072 N cacodylate buffer at pH 
7.4 for 1 hr. After dehydration in increasing concentrations of 
ethanol, samples were embedded in Epon. Thin sections were cut 
from the samples and stained with uranyl acetate and lead citrate. 
Grids were then examined with a Hitachi H-600 transmission 
electron microscope. 
Stage III premelanosomes were observed in all samples, 
therefore verifying that the nodules observed were melanomas. 
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